

FORM PTO-1590
(REV 10-25)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. §371**

MERCK 2033A

U.S. APPLICATION NO. (If known, see 37 CFR §1.5)

10/089166

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PCT/EP00/08940

13 SEPTEMBER 2000

PRIORITY DATE CLAIMED

28 SEPTEMBER 1999

TITLE OF INVENTION

QUINAZOLINONES

APPLICANT(S) FOR DO/EO/US

MEDERSKI, Werner, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. §371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. §371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. §371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 C.F.R. §§1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. §§3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

10089166 .010207

JC02 Rec'd PCT/PTO 22 MAY 2002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :

W. MEDERSKI et al.

Group Art Unit: TBA

Serial No.: 10/089,166

Examiner: TBA

Filed: March 27, 2002

For: QUINAZOLINONES

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to initial examination, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please insert on page 1, after the title:

--This application claims priority of provisional application U.S. Serial No. 60/287,586,
filed September 28, 1999. --


MERCK 2033 A

REMARKS

The amendment to the specification clarifies that the present application claims priority to 60/325,777.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,


Nancy J. Axelrod (Reg. 44,014)
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410


Filed: May 22, 2002

K:\Merck\2033\A\PRE AMD.doc

Quinazolinones

The invention relates to substituted quinazolinones of the formula I

5



in which

10

R and R¹ are independently of each other H, A, OH, OA, OCH₂-Ar, Hal, NH₂, NHA, NA₂, NO₂, CN, C(O)R², CONH₂, CONHA, CONA₂, COOH, COOA or SO₂A,

R² and R³ are independently of each other H, A, -C(=NH)-NH₂ or solid phase,

15

R⁴ is Ar, cycloalkyl, phenylalkyl or Het,

Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms,

Z may be absent and, if present, is phenylene,

A is unbranched or branched alkyl having 1 to 6 carbon atoms,

20

Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,

Het is a saturated, partially or completely unsaturated mono- or

25

bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A, Hal, OH, OA, CF₃, OCF₃, NH₂, NHA, NA₂, COOH, COOA, phenyl which is unsubstituted or mono-, di- or trisubstituted by

30

by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂,

NHA, NA_2 , NO_2 , SO_2NH_2 , SO_2NAH or SO_2NA_2 or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF_3 , OCF_3 , Hal, CN, COOH, COOA, NH_2 , NHA, NA_2 , NO_2 , SO_2NH_2 , SO_2NAH or SO_2NA_2

5 Hal is F, Cl, Br or I,
n is 1, 2 or 3,
m is 0, 1, 2 or 3,

with the proviso

10 if Z and Y are absent and R^4 is phenyl or 4-methoxyphenyl, then R is not H or 6-Cl, R^1 is not H or 8-Cl, R^2 is not H, methyl or ethyl, R^3 is not H, methyl or ethyl and the sum of n and m ($= n+m$) is not 2 or 3,

if Z and Y are absent, R^4 is phenyl or 4-methoxyphenyl and R, R^1 , R^2 and R^3 are H, then the sum of n and m ($= n+m$) is not 2 or 3,

15 if Y is vinyl, R^4 is phenyl, Z is absent, n is 1, m is 1 and R^2 and R^3 are ethyl, then R or R^1 is not NH_2 ,

if Z is absent, Y is absent or vinyl, R^4 is phenyl, phenylalkyl, alkoxyphenyl or pyridyl, R is H and R^1 is NH_2 , then R^2 and R^3 are not A,

and if Z and Y are absent, then R^4 is not phenylalkyl

and their pharmaceutically tolerable salts and solvates.

20

Similar compounds having a quinazolinone parent structure as a combinatorial library are disclosed in WO 98/11438. W.D. Dean et al, J. Het. Chem. 1982, 1117-24 and L. Legrand et al, Bull. Soc. Chim. Fr. 1976, 1853-6 describes methods for the synthesis of similar quinazolinone compounds. Further similar compounds having a quinazolinone parent structure are disclosed in EP 0169537 and US 3,558,610.

25

The invention is based on the object of finding novel compounds having valuable properties, in particular those which can be used for the production of medicaments.

30

It has been found that the compounds of the formula I and their salts or solvates have very valuable pharmacological properties together with good tolerability.

5 They act especially as GPIbIX inhibitors, in particular inhibiting the interaction of this receptor with the ligand von Willebrand factor (vWF). This action can be demonstrated, for example, by a method which is described by S. Meyer et al. in J. Biol. Chem. 1993, 268, 20555-20562. The property as GPIbIX alpha-thrombin receptor (N.J. Greco, Biochemistry 1996, 35, 915-921) can also be blocked by the compounds mentioned.

10

The significance of GPIbIX as an adhesion receptor on platelets, which mediates the primary interaction of platelets with an arteriosclerotically modified vascular wall via binding to the vWF expressed there, has been described by many authors (e.g. Z.M. Ruggeri in Thromb. Hemost. 1997, 15 78, 611-616). The activation of another platelet adhesion receptor, GPIIbIIIa, following the GPIbIX-vWF interaction, leads to platelet aggregation and thus to thrombotic vascular occlusion.

A GPIbIX antagonist can thus prevent the start of thrombus formation and thus also release of active substances from the platelets which, for 20 example, promote thrombus growth and have an additional trophic action on the vascular wall. This has been shown with inhibitory peptides or antibodies in various experimental models (e.g. H Yamamoto et al., Thromb. Hemost. 1998, 79, 202-210).

25

In the case of higher shear forces, the blocking action of GPIbIX inhibitors exerts its maximum effect, as described by J.J. Sixma et al. in Arteriosclerosis, Thrombosis, and Vascular Biology 1996, 16, 64-71. According to the flow chamber method used there, the compounds of the 30 formula I can be characterized as GPIbIX inhibitors in whole blood.


The inhibition of thrombus formation of the GPIbIX inhibitors can be measured by a modified Born method (Nature 1962, 4832, 927-929) using botrocetin or ristocetin as an aggregation stimulant.

5

The compounds of the formula I according to the invention can therefore be employed as pharmaceutical active compounds in human and veterinary medicine. They act as adhesion receptor antagonists, in particular as glycoprotein IbIX antagonists, and are suitable for the prophylaxis and/or therapy of thrombotic disorders and sequelae deriving therefrom. The preferentially best action is to be expected in the case of thrombotic disorders in the arterial vascular system, but GPIbIX inhibitors also have an effect in the case of thrombotic disorders in the venous vascular bed. The disorders are acute coronary syndromes, angina pectoris, myocardial infarct, peripheral circulatory disorders, stroke, transient ischaemic attacks, arteriosclerosis, reocclusion/restenosis after angioplasty/stent implantation. The compounds can furthermore be employed as anti-adhesive substances where the body comes into contact with foreign surfaces such as implants, catheters or cardiac pacemakers.

20

Therefore, the invention relates further to compounds of the formula I



25

in which

R and R¹ are independently of each other H, A, OH, OA, OCH₂-Ar, Hal, NH₂, NHA, NA₂, NO₂, CN, C(O)R², CONH₂, CONHA, CONA₂, COOH, COOA or SO₂A,

30


- R^2 and R^3 are independently of each other H, A, $-C(=NH)-NH_2$ or solid phase,
 R^4 is Ar, cycloalkyl, phenylalkyl or Het,
 Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms,
 5 Z may be absent and, if present, is phenylene,
 A is unbranched or branched alkyl having 1 to 6 carbon atoms,
 Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF_3 , OCF_3 , Hal, CN, COOH, COOA, NH_2 , NHA, NA_2 , NO_2 , SO_2NH_2 , SO_2NAH or SO_2NA_2 ,
 10 Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A, Hal, OH, OA, CF_3 , OCF_3 , NH_2 , NHA, NA_2 , COOH, COOA, phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF_3 , OCF_3 , Hal, CN, COOH, COOA, NH_2 , NHA, NA_2 , NO_2 , SO_2NH_2 , SO_2NAH or SO_2NA_2 or thiophenyl
 15 which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF_3 , OCF_3 , Hal, CN, COOH, COOA, NH_2 , NHA, NA_2 , NO_2 , SO_2NH_2 , SO_2NAH or SO_2NA_2 ,
 20 Hal is F, Cl, Br or I,
 n is 1, 2 or 3,
 25 m is 0, 1, 2 or 3,
 with the proviso
 if Y is vinyl, R^4 is phenyl, Z is absent, n is 1, m is 1 and R^2 and R^3 are ethyl, then R or R^1 is not NH_2 ,
 if Z is absent, Y is absent or vinyl, R^4 is phenyl, phenylalkyl, alkoxyphenyl
 30 or pyridyl, R is H and R^1 is NH_2 , then R^2 and R^3 are not A,

and if Z and Y are absent, then R⁴ is not phenylalkyl
and their physiologically acceptable salts or solvates as pharmaceutical
active compounds.

- 5 The invention relates to compounds of the formula I according to Claim 4
and their physiologically acceptable salts or solvates as glycoprotein IbIX
antagonists.

Comparison medication introduced onto the market which may be
10 mentioned are aspirin and GPIIb/IIIa antagonists.

The invention relates to the compounds of the formula I of claim 1 and their
salts or solvates, and to a process for the preparation of the compounds of
the formula I




in which

- 20 R and R¹ are independently of each other H, A, OH, OA, OCH₂-Ar, Hal,
NH₂, NHA, NA₂, NO₂, CN, C(O)R², CONH₂, CONHA, CONA₂,
CQOH, COOA or SO₂A,
R² and R³ are independently of each other H, A, -C(=NH)-NH₂ or solid
phase,
25 R⁴ is Ar, cycloalkyl, phenylalkyl or Het,
Y may be absent and, if present, is alkenyl having 2 to 4 carbon
atoms,
Z may be absent and, if present, is phenylene,
A is unbranched or branched alkyl having 1 to 6 carbon atoms,

- Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,
- 5 Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A, Hal, OH, OA, CF₃, OCF₃, NH₂, NHA, NA₂, COOH, COOA,
- 10 phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂ or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂,
- 15 NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,
- Hal is F, Cl, Br or I,
- n is 1, 2 or 3,
- m is 0, 1, 2 or 3,
- with the proviso if Z and Y are absent and R⁴ is phenyl or 4-methoxyphenyl,
- 20 then R is not H or 6-Cl, R¹ is not H or 8-Cl, R² is not H, methyl or ethyl, R³ is not H, methyl or ethyl and the sum of n and m (= n+m) is not 2 or 3,
- if Z and Y are absent, R⁴ is phenyl or 4-methoxyphenyl and R, R¹, R² and R³ are H, then the sum of n and m (= n+m) is not 2 or 3,
- if Y is vinyl, R⁴ is phenyl, Z is absent, n is 1, m is 1 and R² and R³ are ethyl,
- 25 then R or R¹ is not NH₂,
- if Z is absent, Y is absent or vinyl, R⁴ is phenyl, phenylalkyl, alkoxyphenyl or pyridyl, R is H and R¹ is NH₂, then R² and R³ are not A,
- and if Z and Y are absent, then R⁴ is not phenylalkyl
- and their pharmaceutically tolerable salts and solvates, characterized in
- 30 that

a) a compound of the formula I is liberated from one of its functional derivatives by treating with a solvolysing or hydrogenolysing agent,
or

b) in stage 1) a compound of the formula II




in which

X is Cl, Br, OH or a reactive esterified OH group


Q is NH₂ or NHA, either of which optionally is protected, and R and R¹ are optionally protected when they are or contain NH₂ or NHA,

is reacted with a compound of the formula III



in which R², R³, Z, n and m have the meanings indicated in Claim 1,

to give a compound of formula IV



in which R, R¹, R², R³, Q, Z, n and m have the meanings indicated above
and

in stage 2) a compound of formula IV as indicated above is if necessary deprotected to give a compound of formula IV in which Q is NH₂ or NHA
and is reacted with a compound of formula V



in which R⁴ and Y have the meanings indicated in Claim 1,

or

c) a radical R, R¹, R², R³ and/or R⁴ is converted into another radical R, R¹, R², R³ and/or R⁴ by, for example

- converting an amino group into a guanidino group by reaction with an amidinating agent,
- 5 - reducing a nitro group, sulfonyl group or sulfoxyl group,
- etherifying an OH group or subjecting an OA group to ether cleavage,
- alkylating a primary or secondary amino group,
- partially or completely hydrolysing a CN group,
- 10 - cleaving an ester group or esterifying a carboxylic acid radical,
- reacting an aryl bromide, aryl iodide, heteroaryl bromide or heteroaryliodide to give the corresponding coupling products by means of a Suzuki coupling with boronic acids,
- or carrying out a nucleophilic or electrophilic substitution,

15 and/or

a base or acid of the formula I is converted into one of its salts or solvates.

The compounds of the formula I can have a chiral centre and therefore occur in a number of stereoisomeric forms. All these forms (e.g. R and S
20 forms) and their mixtures (e.g. the RS forms) are included in the formula I.

The compounds according to the invention also include so-called prodrug derivatives, i.e. compounds of the formula I modified with, for example, alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved
25 in the body to give the active compounds according to the invention.

Furthermore, free amino groups as substituents of compounds of the formula I can be provided with appropriate conventional protective groups. Solvates of the compounds of the formula I are understood as meaning
30 adducts of inert solvent molecules to the compounds of the formula I which

are formed on account of their mutual power of attraction. Solvates are, for example, mono- or dihydrates or alcoholates.

The proviso excludes e.g. the following compounds:

- 5 3-(2-amino-ethyl)-2-p-tolyl-3H-quinazolin-4-one;
- 3-(2-amino-propyl)-2-p-tolyl-3H-quinazolin-4-one;
- 3-(2-amino-ethyl)-2-phenyl-3H-quinazolin-4-one;
- 3-(2-amino-propyl)-2-phenyl-3H-quinazolin-4-one;
- 3-(2-methylamino-ethyl)-2-phenyl-3H-quinazolin-4-one;
- 10 3-(2-methylamino-ethyl)-2-p-tolyl-3H-quinazolin-4-one;
- 3-(2-methylamino-propyl)-2-phenyl-3H-quinazolin-4-one;
- 3-(2-methylamino-propyl)-2-p-tolyl-3H-quinazolin-4-one;
- 3-(2-ethylamino-ethyl)-2-phenyl-3H-quinazolin-4-one;
- 3-(2-ethylamino-ethyl)-2-p-tolyl-3H-quinazolin-4-one;
- 15 3-(2-ethylamino-propyl)-2-phenyl-3H-quinazolin-4-one;
- 3-(2-ethylamino-propyl)-2-p-tolyl-3H-quinazolin-4-one;
- 3-(2-dimethylamino-ethyl)-2-phenyl-3H-quinazolin-4-one;
- 3-(2-dimethylamino-ethyl)-2-p-tolyl-3H-quinazolin-4-one;
- 3-(2-dimethylamino-propyl)-2-phenyl-3H-quinazolin-4-one;
- 20 3-(2-dimethylamino-propyl)-2-p-tolyl-3H-quinazolin-4-one;
- 3-(2-diethylamino-ethyl)-2-phenyl-3H-quinazolin-4-one;
- 3-(2-diethylamino-ethyl)-2-p-tolyl-3H-quinazolin-4-one;
- 3-(2-diethylamino-propyl)-2-phenyl-3H-quinazolin-4-one;
- 3-(2-diethylamino-propyl)-2-p-tolyl-3H-quinazolin-4-one;
- 25 3-(2-methylamino-ethyl)-6-chloro-2-phenyl-3H-quinazolin-4-one;
- 3-(2-methylamino-ethyl)-6-chloro-2-p-tolyl-3H-quinazolin-4-one;
- 3-(2-methylamino-propyl)-6-chloro-2-phenyl-3H-quinazolin-4-one;
- 3-(2-methylamino-propyl)-6-chloro-2-p-tolyl-3H-quinazolin-4-one;
- 3-(2-ethylamino-ethyl)-6-chloro-2-phenyl-3H-quinazolin-4-one;
- 30 3-(2-ethylamino-ethyl)-6-chloro-2-p-tolyl-3H-quinazolin-4-one;

- 3-(2-ethylamino-propyl)-6-chloro-2-phenyl-3H-quinazolin-4-one;
3-(2-ethylamino-propyl)-6-chloro-2-p-tolyl-3H-quinazolin-4-one;
3-(2-dimethylamino-ethyl)-6-chloro-2-phenyl-3H-quinazolin-4-one;
3-(2-dimethylamino-ethyl)-6-chloro-2-p-tolyl-3H-quinazolin-4-one;
5 3-(2-dimethylamino-propyl)-6-chloro-2-phenyl-3H-quinazolin-4-one;
3-(2-dimethylamino-propyl)-6-chloro-2-p-tolyl-3H-quinazolin-4-one;
3-(2-diethylamino-ethyl)-6-chloro-2-phenyl-3H-quinazolin-4-one;
3-(2-diethylamino-ethyl)-6-chloro-2-p-tolyl-3H-quinazolin-4-one;
3-(2-diethylamino-propyl)-6-chloro-2-phenyl-3H-quinazolin-4-one;
10 3-(2-diethylamino-propyl)-6-chloro-2-p-tolyl-3H-quinazolin-4-one;
3-(2-methylamino-ethyl)-8-chloro-2-phenyl-3H-quinazolin-4-one;
3-(2-methylamino-ethyl)-8-chloro-2-p-tolyl-3H-quinazolin-4-one;
3-(2-methylamino-propyl)-8-chloro-2-phenyl-3H-quinazolin-4-one;
3-(2-methylamino-propyl)-8-chloro-2-p-tolyl-3H-quinazolin-4-one;
15 3-(2-ethylamino-ethyl)-8-chloro-2-phenyl-3H-quinazolin-4-one;
3-(2-ethylamino-ethyl)-8-chloro-2-p-tolyl-3H-quinazolin-4-one;
3-(2-ethylamino-propyl)-8-chloro-2-phenyl-3H-quinazolin-4-one;
3-(2-ethylamino-propyl)-8-chloro-2-p-tolyl-3H-quinazolin-4-one;
3-(2-dimethylamino-ethyl)-8-chloro-2-phenyl-3H-quinazolin-4-one;
20 3-(2-dimethylamino-ethyl)-8-chloro-2-p-tolyl-3H-quinazolin-4-one;
3-(2-dimethylamino-propyl)-8-chloro-2-phenyl-3H-quinazolin-4-one;
3-(2-dimethylamino-propyl)-8-chloro-2-p-tolyl-3H-quinazolin-4-one;
3-(2-diethylamino-ethyl)-8-chloro-2-phenyl-3H-quinazolin-4-one;
3-(2-diethylamino-ethyl)-8-chloro-2-p-tolyl-3H-quinazolin-4-one;
25 3-(2-diethylamino-propyl)-8-chloro-2-phenyl-3H-quinazolin-4-one;
3-(2-diethylamino-propyl)-8-chloro-2-p-tolyl-3H-quinazolin-4-one;
3-(2-methylamino-ethyl)-6,8-dichloro-2-phenyl-3H-quinazolin-4-one;
3-(2-methylamino-ethyl)-6,8-dichloro-2-p-tolyl-3H-quinazolin-4-one;
3-(2-methylamino-propyl)-6,8-dichloro-2-phenyl-3H-quinazolin-4-one;
30 3-(2-methylamino-propyl)-6,8-dichloro-2-p-tolyl-3H-quinazolin-4-one;

- 3-(2-ethylamino-ethyl)-6,8-dichloro-2-phenyl-3H-quinazolin-4-one;
 3-(2-ethylamino-ethyl)-6,8-dichloro-2-p-tolyl-3H-quinazolin-4-one;
 3-(2-ethylamino-propyl)-6,8-dichloro-2-phenyl-3H-quinazolin-4-one;
 3-(2-ethylamino-propyl)-6,8-dichloro-2-p-tolyl-3H-quinazolin-4-one;
 5 3-(2-dimethylamino-ethyl)-6,8-dichloro-2-phenyl-3H-quinazolin-4-one;
 3-(2-dimethylamino-ethyl)-6,8-dichloro-2-p-tolyl-3H-quinazolin-4-one;
 3-(2-dimethylamino-propyl)-6,8-dichloro-2-phenyl-3H-quinazolin-4-one;
 3-(2-dimethylamino-propyl)-6,8-dichloro-2-p-tolyl-3H-quinazolin-4-one;
 3-(2-diethylamino-ethyl)-6,8-dichloro-2-phenyl-3H-quinazolin-4-one;
 10 3-(2-diethylamino-ethyl)-6,8-dichloro-2-p-tolyl-3H-quinazolin-4-one;
 3-(2-diethylamino-propyl)-6,8-dichloro-2-phenyl-3H-quinazolin-4-one;
 3-(2-diethylamino-propyl)-6,8-dichloro-2-p-tolyl-3H-quinazolin-4-one and
 6-amino-3-(2-diethylamino-ethyl)-2-styryl-3H-quinazolin-4-one.

15 The abbreviations used have the following meanings:

- BOC tert-butoxycarbonyl,
 CBZ benzyloxycarbonyl,
 DBU 1,8-diazabicyclo[5.4.0]undec-7-ene,
 DCC dicyclohexylcarbodiimide,
 20 DCE dichloroethane,
 DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone,
 DMA dimethylacetamide,
 DMF dimethylformamide,
 dppf 1,1'-bis(diphenylphosphino)ferrocene,
 25 Et ethyl,
 Fmoc fluorenylmethoxycarbonyl,
 HBTU O-(benzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluoro
 phosphate,
 Me methyl,
 30 Mtr 4-methoxy-2,3,6-trimethylphenylsulfonyl,

- OBut tert-butyl ester,
 OMe methyl ester,
 OEt ethyl ester,
 POA phenoxyacetyl,
 5 Ph phenyl,
 TEA triethylamine,
 TFA trifluoroacetic acid.

- 10 In the above formulae, A is alkyl and has 1 to 6, preferably 1, 2, 3 or 4 C atoms. Alkyl is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, additionally also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 15 1,2,2-trimethylpropyl.
- A is preferentially methyl.

- Alkenyl having 2 to 4 carbon atoms is preferably vinyl or buta-1,3-dienyl, vinyl is particularly preferred.
- 20

- Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂.

- 25 Ar is preferentially phenyl, preferably - as indicated - mono- di- or trisubstituted phenyl, specifically preferentially phenyl, 2-, 3- or 4-methylphenyl, 2-, 3- or 4-ethylphenyl, 2-, 3- or 4-propylphenyl, 2-, 3- or 4-isopropylphenyl, 2-, 3- or 4-tert-butylphenyl, 2-, 3- or 4-aminophenyl, 2-, 3- or 4-N,N-dimethylaminophenyl, 2-, 3- or 4-sulfonamidophenyl, 2-, 3- or 30 4-nitrophenyl, 2-, 3- or 4-hydroxyphenyl, 2-, 3- or 4-methoxyphenyl, 2-, 3-

or 4-ethoxyphenyl, 2-, 3- or 4-trifluoromethylphenyl, 2-, 3- or 4-trifluoromethoxyphenyl, 2-, 3- or 4-carboxyphenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-chlorophenyl, 2-, 3- or 4-bromophenyl. Furthermore Ar is preferentially unsubstituted naphthyl, biphenyl or
 5 benzofuran-5-yl.

Phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-tert-butylphenyl, 4-dimethylaminophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 3-chlorophenyl, 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, 2,5-
 10 dimethoxyphenyl, 3',5'-dimethoxybiphenyl-4-yl, 2',4'-dimethoxybiphenyl-4-yl, biphenyl-4-yl, naphthalen-1-yl, naphthalen-2-yl or benzofuran-5-yl is particularly preferred for Ar.

Cycloalkyl preferably has 3-7 C atoms and is preferably cyclopropyl or
 15 cyclobutyl, furthermore preferably cyclopentyl or cyclohexyl, and further also cycloheptyl; cyclohexyl is particularly preferred.

Hal is preferably F, Cl or Br.

20 Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A, Hal, OH, OA, CF₃, OCF₃, NH₂, NHA, NA₂, COOH, COOA, phenyl which is unsubstituted or mono-, di- or trisubstituted
 25 by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂ or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂.

Het is preferably substituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂ or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂ or unsubstituted 2- or 3-furyl, 2- or 3-thiophenyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -4- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4-4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothieryl, 1-, 2-, 3-, 4-, 5-, 6- or 7-1H-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolinyl, 1-, 2-, 3-, 4- or 9-carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl. The heterocyclic radicals can also be partially or completely hydrogenated. Het can thus also be 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or -5-furyl, tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -3-pyrrolyl, tetrahydro-1-, -2- or 4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4-, -5-, -6-, -7-1H-indolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl,

- 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl,
1,2,3,6-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or
4-piperidinyl, 1-, 2-, 3- or 4-azepanyl, 2-, 3- or 4-morpholinyl,
tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, -4- or
5 -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or
-5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-,
-4-, -5-, -6-, -7- or -8-quinolinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-,
-4-, -5-, -6-, -7- or -8-isoquinolinyl.
- 10 2-Furyl, thiophen-2-yl, thiophen-3-yl, 5-(3,4-dimethoxyphenyl)-thiophen-2-yl
or 5-[2,2']bithiophenyl is particularly preferred for Het.

- Phenylalkyl preferably has 7, 8, 9 or 10 carbon atoms and is preferably
phenylmethyl, phenylethyl, phenylpropyl or phenylbutyl; phenylethyl is
15 particularly preferred.

- The term solid phase indicates a resin for solid-phase chemistry, especially
for combinatorial chemistry, i.e. by robot- and computer-assisted
syntheses, and subjected to mass screening as indicated in US 5,463,564;
20 M. A. Gallop et al., J. Med. Chem. 1994, 37, 1233-1251 and 1385-1401
and M.J. Sofia, Drugs Discovery Today 1996, 1, 27-34). The polymeric
material of the solid phase is generally chosen from the group consisting of
cross-linked polystyrene, cross-linked polyacrylamide or other resins,
natural polymers or silicagels.

- 25 The group of cross-linked polystyrene, cross-linked polyacrylamide or other
resins includes e.g. polyacrylamide, polymethacrylamide,
polyhydroxyethylmethacrylate, polyamide, polystyrene, (meth)acrylate
copolymers, for instance from (meth)acrylic acid, esters of (meth)acrylic

acid and/or 2-methylene-succinic acid, but-2-enoic acid or maleic acid, polyurethanes or other copolymers.

5 Suitable terminal functional groups or linkers on the surface of the resin have to be chosen to attach the compounds to the resin. There exists a variety of commercially available resins, e.g. in Novabiochem - The Combinatorial Chemistry Catalog, March 99. Examples for suitable resins are carbonate resins with a modified carbonate group as terminal functional group like p-nitrophenylcarbonate resin, halogenated resins like Merrifield
10 resin (chloromethylpolystyrene) or carboxy resins like carboxy polystyrene resin or NovaSyn® TG Carboxy Resin. p-Nitrophenylcarbonate resin is particularly preferred. These and other types of resins well known in the art can be used in the subject invention.

15 R and R¹ are independently of each other H, A, OH, OA, OCH₂-Ar, Hal, NH₂, NHA, NA₂, NO₂, CN, C(O)R², CONH₂, CONHA, CONA₂, COOH, COOA or SO₂A, where A, Ar, Hal have a preferred meaning indicated beforehand and R² have a preferred meaning indicated in the following.

20 R is preferentially H.

R¹ is preferentially H, A, OA or Hal.

The preferred position of R¹ is the 6- or 7-position of the quinazolinone ring system.

25 R² and R³ are independently of each other H, A, -C(=NH)-NH₂ or a solid phase, where A or solid phase have a preferred meaning indicated beforehand.

R² is preferentially H.

30 R³ is preferentially H or -C(=NH)-NH₂, particularly preferred is H.

R⁴ is Ar, phenylalkyl, cycloalkyl or Het, where Ar, phenylalkyl, cycloalkyl or Het have a preferred meaning indicated beforehand. R⁴ is preferentially phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-tert-butylphenyl, 4-dimethylaminophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 3-chlorophenyl, 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 3',5'-dimethoxybiphenyl-4-yl, 2',4'-dimethoxybiphenyl-4-yl, biphenyl-4-yl, naphthalen-1-yl, naphthalen-2-yl or benzofuran-5-yl, phenylethyl, cyclohexyl, 2-furyl, thiophen-2-yl, thiophen-3-yl, 5-(3,4-dimethoxyphenyl)-thiophen-2-yl or 5-[2,2']bithiophenyl.

Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms. Y is preferentially absent or vinyl.

Z may be absent and, if present, is phenylene.

n is 1, 2 or 3, particularly preferred 1.

m is 0, 1, 2 or 3, particularly preferred 1.


Some preferred groups of compounds can be expressed by the following subformulae Ia to Iv, which correspond to the formula I and in which the radicals not designated in greater detail have the meanings indicated in formula I, but in which

in Ia R is H and
 R¹ is H, A, OA or Hal;

in Ib R is H,
 R¹ is H, A, OA or Hal and

 Y is absent;

in Ic R is H,
 R¹ is H, A, OA or Hal,
 Y is absent and
 Z is absent;



10

in Id R is H,
 R¹ is H, A, OA or Hal,
 R⁴ is Ar, cycloalkyl or Het,
 Y is absent and
 Z is absent;


15

in Ie R is H,
 R¹ is H, A, OA or Hal,
 R⁴ is Het,
 Y is absent and
 Z is absent;

20

in If R is H,
 R¹ is H, A, OA or Hal,
 Y is absent and
 Z is phenylene;

25



- in Ig R is H,
 R¹ is H, A, OA or Hal and
 Y is alkenyl having 2 to 4 carbon atoms;
- 5 in Ih R is H,
 R¹ is H, A, OA or Hal,
 Y is alkenyl having 2 to 4 carbon atoms and
 Z is absent;
- 10 in li R is H,
 R¹ is H, A, OA or Hal,
 Y is alkenyl having 2 to 4 carbon atoms and
 Z is phenylene;
- 15 in lj R is H,
 R¹ is H, A, OA or Hal,
 R² is H and
 R⁴ is Ar;
- 20 in lk R is H,
 R¹ is H, A, OA or Hal,
 R² is H and
 R⁴ is phenylalkyl;
- 25 in lm R is H,
 R¹ is H, A, OA or Hal,
 R² is H and
 R⁴ is cycloalkyl;
- 30 in ln R is H,

R¹ is H, A, OA or Hal,

R² is H and

R⁴ is Het;

5 in lo R is H,
 R¹ is H, A, OA or Hal,
 R² is H,
 R³ is H,
 R⁴ is phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-
 10 tert-butylphenyl, 4-dimethylaminophenyl, 4-methoxyphenyl, 3-
 methoxyphenyl, 3-chlorophenyl, 3,4,5-trimethoxyphenyl, 3,4-
 dimethoxyphenyl, 2,5-dimethoxyphenyl, 3',5'-dimethoxy-
 biphenyl-4-yl, 2',4'-dimethoxybiphenyl-4-yl, biphenyl-4-yl,
 naphthalen-1-yl, naphthalen-2-yl or benzofuran-5-yl,
 15 phenylethyl, cyclohexyl, 2-furyl, thiophen-2-yl, thiophen-3-yl,
 5-(3,4-dimethoxyphenyl)-thiophen-2-yl or 5-[2,2']bithiophenyl,
 Z is absent,
 n is 1 and
 m is 1;

20

 in lp R is H,
 R¹ is H, A, OA or Hal,
 R² is H,
 R³ is H,
 25 R⁴ is phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-
 tert-butylphenyl, 4-dimethylaminophenyl, 4-methoxyphenyl, 3-
 methoxyphenyl, 3-chlorophenyl, 3,4,5-trimethoxyphenyl, 3,4-
 dimethoxyphenyl, 2,5-dimethoxyphenyl, 3',5'-dimethoxy-
 biphenyl-4-yl, 2',4'-dimethoxybiphenyl-4-yl, biphenyl-4-yl,
 30 naphthalen-1-yl, naphthalen-2-yl or benzofuran-5-yl,

phenylethyl, cyclohexyl, 2-furyl, thiophen-2-yl, thiophen-3-yl,
5-(3,4-dimethoxyphenyl)-thiophen-2-yl or 5-[2,2']bithiophenyl,

Z is phenylene,

n is 1 and

5 m is 1;

in Iq R is H,

R¹ is H, A, OA or Hal,

R² is H,

10 R³ is H,

Y is -CH=CH-,

R⁴ is phenyl, 4-dimethylaminophenyl or 2,5-dimethoxyphenyl,

Z is absent,

n is 1 and

15 m is 1;

in Ir R is H,

R¹ is H, A, OA or Hal,

R² is H,

20 R³ is H,

Y is -CH=CH-,

R⁴ is phenyl, 4-dimethylaminophenyl or 2,5-dimethoxyphenyl,

Z is phenylene,

n is 1 and

25 m is 1;

in Is R is H,

R¹ is H, A, OA or Hal,

R² is H,

30 R³ is H,

Y is absent,

R⁴ is phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-tert-butylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, 3-chlorophenyl, 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, 3',5'-dimethoxybiphenyl, 2',4'-dimethoxybiphenyl-4-yl, biphenyl-4-yl, naphthalen-1-yl, naphthalen-2-yl or benzofuran-5-yl, phenylethyl, cyclohexyl, 2-furyl, thiophen-2-yl, thiophen-3-yl, 5-(3,4-dimethoxyphenyl)-thiophen-2-yl or 5-[2,2']bithiophenyl,

10 Z is absent,

n is 1 and

m is 1;

in It R is H,

15 R¹ is H, A, OA or Hal,

R² is H,

R³ is H,

Y is absent,

20 R⁴ is phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-tert-butylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, 3-chlorophenyl, 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, 3',5'-dimethoxybiphenyl-4-yl, 2',4'-dimethoxybiphenyl-4-yl, biphenyl-4-yl, naphthalen-1-yl, naphthalen-2-yl or benzofuran-5-yl, phenylethyl, cyclohexyl, 2-furyl, thiophen-2-yl, thiophen-3-yl, 5-(3,4-dimethoxyphenyl)-thiophen-2-yl or 5-[2,2']bithiophenyl,


25

Z is phenylene,

n is 1 and

m is 1;

in Iu



5

R and R¹ are independently of each other H, A, OH, OA, OCH₂-Ar, Hal, NH₂, NHA, NA₂, NO₂, CN, C(O)R², CONH₂, CONHA, CONA₂, COOH, COOA or SO₂A,

10

R² and R³ are independently of each other H, A, -C(=NH)-NH₂ or solid phase,

R⁴ is Ar, cycloalkyl, phenylalkyl or Het,

Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms,

A is unbranched or branched alkyl having 1 to 6 carbon atoms,

15

Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,

20

Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A, Hal, OH, OA, CF₃, OCF₃, NH₂, NHA, NA₂, COOH, COOA, phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂ or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂

25

30

Hal

is F, Cl, Br or I,

n is 1, 2 or 3,

m is 0, 1, 2 or 3,


with the proviso if Y is absent and R⁴ is phenyl or 4-methoxyphenyl, then R is not H or 6-Cl, R¹ is not H or 8-Cl, R² is not H, methyl or ethyl, R³ is not H, methyl or ethyl and the sum of n and m (= n+m) is not 2 or 3,

if Y is absent, R⁴ is phenyl or 4-methoxyphenyl, R, R¹, R² and R³ are H, then the sum of n and m (= n+m) is not 2 or 3,

if Y is vinyl, R⁴ is phenyl, Z is absent, n is 1, m is 1 and R² and R³ are ethyl, then R or R¹ is not NH₂,

if Z is absent, Y is absent or vinyl, R⁴ is phenyl, phenylalkyl, alkoxyphenyl or pyridyl, R is H and R¹ is NH₂, then R² and R³ are not A, and if Z and Y are absent, then R⁴ is not phenylalkyl and their pharmaceutically tolerable salts and solvates;

15 in iv



20 R and R¹ are independently of each other H, A, OH, OA, OCH₂-Ar, Hal, NH₂, NHA, NA₂, NO₂, CN, C(O)R², CONH₂, CONHA, CONA₂, COOH, COOA or SO₂A,

R² and R³ are independently of each other H, A, -C(=NH)-NH₂ or solid phase,

25 R⁴ is Ar, cycloalkyl, phenylalkyl or Het,

Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms,

A is unbranched or branched alkyl having 1 to 6 carbon atoms,

Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is

30 unsubstituted or mono-, di- or trisubstituted by A, OH, OA,

CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂,
SO₂NH₂, SO₂NAH or SO₂NA₂,

Het is a saturated, partially or completely unsaturated mono- or
bicyclic heterocyclic radical having 5 to 10 ring members,
5 where 1 or 2 N and/or 1 or 2 S or O atoms can be present and
the heterocyclic radical can be mono- or disubstituted by A,
Hal, OH, OA, CF₃, OCF₃, NH₂, NHA, NA₂, COOH, COOA,
phenyl which is unsubstituted or mono-, di- or trisubstituted by
by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂,
10 NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂ or thiophenyl
which is unsubstituted or mono-, di- or trisubstituted by A, OH,
OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂,
NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂

Hal is F, Cl, Br or I,

15 n is 1, 2 or 3,

m is 0, 1, 2 or 3,

and their pharmaceutically tolerable salts and solvates.

20

The compounds of the formula I and also the starting substances for their
preparation are otherwise prepared by methods known per se, such as are
described in the literature (e.g. in the standard works such as Houben-
Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry],
25 Georg-Thieme-Verlag, Stuttgart), namely under reaction conditions which
are known and suitable for the reactions mentioned. In this case, use can
also be made of variants which are known per se, but not mentioned here
in greater detail.

The starting substances, if desired, can also be formed in situ such that they are not isolated from the reaction mixture, but immediately reacted further to give the compounds of the formula I.

- 5 The compounds of the formula I can be obtained by liberating them from their functional derivatives by solvolysis, in particular hydrolysis or by hydrogenolysis.

10 Preferred starting substances for the solvolysis or hydrogenolysis are those which otherwise correspond to the formula I, but instead of one or more free amino and/or hydroxyl groups contain corresponding protected amino and/or hydroxyl groups, in particular those which instead of an H-N- group carry an R'-N- group, in which R' is an amino protective group and/or those which instead of the H atom of a hydroxyl group carry a hydroxyl protective
15 group; e.g. those which correspond to the formula I, but instead of a group -COOH carry a group -COOR", in which R" is a hydroxyl protective group.

A number of - identical or different - protected amino and/or hydroxyl groups can also be present in the molecule of the starting substance. If the
20 protective groups present are different from one another, in many cases they can be removed selectively (lit.: T.W. Greene, P.G.M. Wuts, *Protective Groups in Organic Chemistry*, 2nd ed., Wiley, New York 1991 or P.J. Kocienski, *Protecting Groups*, 1st ed., Georg Thieme Verlag, Stuttgart - New-York, 1994).

25

The expression "amino protective group" is generally known and relates to groups which are suitable for protecting (for blocking) an amino group against chemical reactions, but which are easily removable after the desired chemical reaction has been carried out at other positions in the
30 molecule. Typical groups of this type are, in particular, unsubstituted or

substituted acyl, aryl, aralkoxymethyl or aralkyl groups. Since the amino protective groups are removed after the desired reaction (or reaction sequence), their nature and size is otherwise not critical; however, those having 1-20, in particular 1-8, C atoms are preferred. The expression "acyl group" is to be interpreted in the widest sense in connection with the present process. It includes acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids and, in particular, alkoxy carbonyl groups, aryloxy carbonyl groups and especially aralkoxy carbonyl groups. Examples of acyl groups of this type are alkanoyl such as acetyl, propionyl, butyryl; aralkanoyl such as phenylacetyl; aroyl such as benzoyl or toluyl; aryloxyalkanoyl such as POA; alkoxy carbonyl such as methoxy carbonyl, ethoxy carbonyl, 2,2,2-trichloroethoxy carbonyl, BOC, 2-iodoethoxy carbonyl; aralkyloxy carbonyl such as CBZ ("carbobenzoxy"), 4-methoxybenzyloxy carbonyl (MOZ), 4-Nitro-benzyloxy carbonyl oder 9-fluorenylmethoxy carbonyl (Fmoc); 2-(phenylsulfonyl)ethoxy carbonyl; trimethylsilylethoxy carbonyl (Troc) or arylsulfonyl such as 4-methoxy-2,3,6-trimethylphenyl-sulfonyl (Mtr). Preferred amino protective groups are BOC, furthermore CBZ, Fmoc, benzyl and acetyl; particularly preferred Fmoc.

The expression "hydroxyl protective group" is also generally known and relates to groups which are suitable for protecting a hydroxyl group against chemical reactions, but which are easily removable after the desired chemical reaction has been carried out at other positions in the molecule.

Typical groups of this type are the abovementioned unsubstituted or substituted aryl, aralkyl, aroyl or acyl groups, furthermore also alkyl groups, alkyl-, aryl- or aralkylsilyl groups or O,O- or O,S-acetals. The nature and size of the hydroxyl protective groups is not critical, since they are removed again after the desired chemical reaction or reaction sequence; groups

having 1-20, in particular 1-10 C atoms, are preferred. Examples of hydroxyl protective groups are, inter alia, benzyl, 4-methoxybenzyl oder 2,4-dimethoxybenzyl, aroyl groups such as benzoyl or p-nitrobenzoyl, acyl groups such as acetyl or pivaloyl, p-toluolsulfonyl, alkyl groups such as methyl or tert-butyl, but also allyl, alkylsilyl groups such as trimethylsilyl (TMS), triisopropylsilyl (TIPS), tert-butyldimethylsilyl (TBS) or triethylsilyl, trimethylsilylethyl, aralkylsilyl groups such as tert-butyldiphenylsilyl (TBDPS), cyclic acetals such as isopropylidene-, cyclopentylidene-, cyclohexylidene-, benzylidene-, p-methoxybenzylidene- or o,p-dimethoxybenzylideneacetal, acyclic acetals such as tetrahydropyranyl (Thp), methoxymethyl (MOM), methoxyethoxymethyl (MEM), benzyloxymethyl (BOM) or methylthiomethyl (MTM). Acetyl, benzyl, tert-butyl or TBS being particularly preferred.

15 The liberation of the compounds of the formula I from their functional derivatives depending on the protective group used is known in the present literature such as T.W. Greene, P.G.M. Wuts, *Protective Groups in Organic Chemistry*, 2nd ed., Wiley, New York 1991, P.J. Kocienski, *Protecting Groups*, 1st ed., Georg Thieme Verlag, Stuttgart - New-York, 1994. In this case, use can also be made of variants which are known per se, but not mentioned here in greater detail.

25 The groups BOC and O-tert-butyl can preferably be removed, for example, using TFA in dichloromethane or using approximately 3 to 5N HCl in dioxane at 15-30°C, the Fmoc group using an approximately 5 to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15-30°C.

30 Preferred starting substances for the solvolysis or hydrogenolysis includes also those which otherwise correspond to the formula I, but are attached to a solid phase. The liberation of the compounds of the formula I from the

solid phase is known in the present literature such as Novabiochem - The Combinatorial Chemistry Catalog, March 99 and cited literature.

5 The solid phase with a carbonate moiety as terminal functional group can preferably be removed, for example, using TFA (50%) in dichloromethane.

10 The quinazolinones of formula I can also preferably be prepared, using either solution or solid-phase techniques, by combining and reacting an anthranilic acid of formula II with an amine of formula III and if necessary deprotect the given formula IV in which Q is then NH_2 or NHA and reacting the compound of formula IV in which Q is NH_2 or NHA with an aldehyde of formula V.

15 As a rule, the starting compounds of the formulae II, III and V are known or commercially available.

The unknown compounds, however, can be prepared by methods known per se. The compounds of the formula II are anthranilic acids. It is furthermore possible to introduce appropriate substituents into the aromatic by conventional electrophilic or alternatively nucleophilic substitutions.

20 Examples of Fmoc protected anthranilic acids, include, but are not limited to, Fmoc protected anthranilic acid, Fmoc protected 3-methyl anthranilic acid, Fmoc protected 3-methoxy anthranilic acid, Fmoc protected 3-chloro anthranilic acid or Fmoc protected 4-chloro anthranilic acid.

25 Solid-phase techniques may be employed to condense anthranilic acids of formula II and the amine component of formula III which is resin bound (R^2 or R^3 is solid phase).

The amines of formula III in which R^2 or R^3 are H, as a rule, are also commercially available and can be attached to the suitable resin by

30 coupling procedures well known in the art and as described in the ensuing

Examples. Furthermore, syntheses for the preparation of amines of formula III, such as, for example, the Gabriel synthesis, can be used.

The aldehydes of formula V, as a rule, are also commercially available.

5 Furthermore, syntheses for the preparation of aldehydes of formula V, such as, for example, the oxidation of an alcohol, can be used.

As a rule, the reactions and the attachment to the resin are carried out in an inert solvent. Depending on the conditions used, the reaction time is
10 between a few minutes and a number of days, the reaction temperature between approximately 0° and 150°C, normally between 20° and 130°C. Suitable inert solvents are, for example, hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride,
15 chloroform or dichloromethane; alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); ketones such as
20 acetone or butanone; amides such as acetamide, N-methylpyrrolidone (NMP), dimethylacetamide or dimethylformamide (DMF); nitriles such as acetonitrile; sulfoxides such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids such as formic acid or acetic acid; nitro compounds such as nitromethane or nitrobenzene; esters such as ethyl
25 acetate or mixtures of the solvents mentioned.

The reaction of the compounds of formula II with compounds of formula III is analogously to the coupling of peptides. The condensation reaction of formula II with formula III is preferably carried out in an inert solvent as
30 indicated above in the presence of a dehydrating agent, such as,

dicyclohexylcarbodiimide (DCC), N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide-hydrochlorid (EDC) or diisopropylcarbodiimide (DIC), further for instance in the presence of an anhydride of propanphosphonic acid (see Angew. Chem. 1980, 92, 129), diphenylphosphorylazide or 2-ethoxy-N-ethoxycarbonyl-1,2-dihydroquinoline.

Particularly preferred is the presence of a coupling agent, such as TBTU (O-(benzotriazol-1-yl)-N,N,N',N'-bis-(tetramethylene)-uronium tetrafluoroborate) or O-(benzotriazol-1-yl)-N,N,N',N'-bis-(tetramethylene)-uronium hexafluorophosphate.

A compound of formula II in which X is a reactive esterified OH group can be synthesized by reacting a compound of formula II in which X is OH with HOBT (1-hydroxybenzotriazole) or N-hydroxysuccinimide (e.g. in the standard works such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart).

For the preparation of compounds of the formula I in which R^2 or R^3 are $-C(=NH)-NH-$, a compound of formula I in which R^2 and R^3 are H can be treated with an amidinating agent. The preferred amidinating agent is 1-amidino-3,5-dimethylpyrazole (DPFN), which is employed, in particular, in the form of its nitrate, or pyrazole-1-carboxamidine. The reaction is expediently carried out with addition of a base such as triethylamine or ethyldiisopropylamine in an inert solvent or solvent mixture, e.g. DMF at temperatures between 0° and 150°C , preferably between 60° and 120°C .

For the preparation of compounds of the formula I in which R^4 is unsubstituted or substituted biphenyl, 5-(3,4-dimethoxyphenyl)-thiophen-2-yl or 5-[2,2']bithiophenyl, an appropriate compound of the formula I in which R^4 is phenyl chloride, phenyl bromide, phenyl iodide, thiophenyl chloride,


- thiophenyl bromide or thiophenyl iodide can be reacted with the appropriate boronic acid derivatives in a Suzuki type coupling reaction. This reaction is expediently carried out under Palladium catalysis with different Phosphines as coordination ligands, e.g. $\text{Pd}(\text{P}(\text{Ph})_3)_2$, $\text{Pd}(\text{II})\text{Cl}_2\text{dppf}$, $\text{PdOAc}_2 + \text{P}(\text{R}^*)_3$ (5 $\text{R}^* = \text{phenyl, cyclohexyl, tert-butyl}$) etc. in the presence of a base such as potassium carbonate, caesium carbonate, DBU, NaOH, in an inert solvent or solvent mixture, e.g. DMF or 1,4-dioxane at temperatures between 0° and 150° , preferably between 60° and 120° . Depending on the conditions used, the reaction time is between a few minutes and a number of days.
- 10 The boronic acid derivatives can be prepared by conventional methods or are commercially available. The reactions can be carried out in analogy to the methods indicated in Suzuki et al., J. Am. Chem. Soc. 1989, 111, 314ff., Suzuki et al., Chem. Rev. 1995, 95, 2457ff and G.C. Fu et al. Angew. Chem 1998, 110, 3586.
- 15 A base of the formula I can be converted into the associated acid addition salt using an acid, for example by reaction of equivalent amounts of the base and of the acid in an inert solvent such as ethanol and subsequent evaporation. Acids which give physiologically acceptable salts are
- 20 particularly suitable for this reaction. Thus inorganic acids can be used, e.g. sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric
- 25 acids, e.g. formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or ethanesulfonic acid, p-toluenesulfonic acid, naphthalenemono- and disulfonic acids or
- 30 laurylsulfuric acid. Salts with physiologically unacceptable acids, e.g.

picrates, can be used for the isolation and/or purification of the compounds of the formula I.

On the other hand, compounds of the formula I with bases (e.g sodium or potassium hydroxide or carbonate) can be converted into the
 5 corresponding metal salts, in particular alkali metal or alkaline earth metal salts, or into the corresponding ammonium salts.

The invention furthermore relates to pharmaceutical preparations comprising at least one compound of the formula I

10



in which

15 R and R¹ are independently of each other H, A, OH, OA, OCH₂-Ar, Hal, NH₂, NHA, NA₂, NO₂, CN, C(O)R², CONH₂, CONHA, CONA₂, COOH, COOA or SO₂A,

R² and R³ are independently of each other H, A, -C(=NH)-NH₂ or solid phase,

20 R⁴ is Ar, cycloalkyl, phenylalkyl or Het,

Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms,

Z may be absent and, if present, is phenylene,

A is unbranched or branched alkyl having 1 to 6 carbon atoms,

25 Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,

30 Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members,

where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A, Hal, OH, OA, CF₃, OCF₃, NH₂, NHA, NA₂, COOH, COOA, phenyl which is unsubstituted or mono-, di- or trisubstituted by
 5 by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂ or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂

10 Hal is F, Cl, Br or I,
 n is 1, 2 or 3,
 m is 0, 1, 2 or 3,

with the proviso

if Y is vinyl, R⁴ is phenyl, Z is absent, n is 1, m is 1 and R² and R³ are ethyl,
 15 then R or R¹ is not NH₂,

if Z is absent, Y is absent or vinyl, R⁴ is phenyl, phenylalkyl, alkoxyphenyl

or pyridyl, R is H and R¹ is NH₂, then R² and R³ are not A,

and if Z and Y are absent, then R⁴ is not phenylalkyl

and/or one of its physiologically acceptable salts, which are prepared, in
 20 particular, in a non-chemical way. In this case, the compounds of the formula I according to Claim 4 can be brought into a suitable dose form together with at least one solid, liquid and/or semi-liquid excipient or auxiliary and, if appropriate, in combination with one or more other active
 25 compounds.

25

These preparations can be used as medicaments in human or veterinary medicine. Possible excipients are organic or inorganic substances which are suitable for enteral (e.g. oral) or parenteral administration or topical application and do not react with the novel compounds, for example water,
 30 vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols,

glyceryl triacetate, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc and petroleum jelly. Tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops are used, in particular, for oral administration, suppositories are used for rectal administration, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants, are used for parenteral administration, and ointments, creams or powders are used for topical application. The novel compounds can also be lyophilized and the lyophilizates obtained used, for example, for the production of injection preparations. The preparations indicated can be sterilized and/or can contain auxiliaries such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffer substances, colourants, flavourings and/or one or more other active compounds, e.g. one or more vitamins.

15. The compounds of the formula I and their physiologically acceptable salts act as adhesion receptor antagonists, in particular glycoprotein IbIX antagonists, and can be employed for the prophylaxis and/or therapy of thrombotic disorders and sequelae deriving therefrom. The disorders are acute coronary syndromes, angina pectoris, myocardial infarct, peripheral circulatory disorders, stroke, transient ischaemic attacks, arteriosclerosis and reocclusion/restenosis after angioplasty/stent implantation.

In this case, the substances according to the invention are as a rule administered in the dose of the glycoprotein IIbIIIa antagonist ReoPro® of preferably between approximately 1 and 500 mg, in particular between 5 and 100 mg, per dose unit. The daily dose is preferably between approximately 0.02 and 10 mg/kg of body weight. The specific dose for each patient depends, however, on all sorts of factors, for example on the efficacy of the specific compound employed, on the age, body weight, general state of health and sex, on the diet, on the time and route of

administration, and on the excretion rate, pharmaceutical combination and severity of the particular disorder to which the therapy applies. Oral administration is preferred.

- 5 Above and below, all temperatures are indicated in °C. In the following examples, "customary working-up" for solution reactions means: if necessary, water is added, if necessary, depending on the constitution of the final product, the mixture is adjusted to pHs between 2 and 10 and extracted with ethyl acetate or dichloromethane, the organic phase is
10 separated off, dried over sodium sulfate and evaporated, and the residue is purified by chromatography on silica gel and/or by crystallization.

- "Customary working-up" for solid-phase reactions means: the crude reaction is filtered and washed with DMF twice, then successively with
15 methanol and methylene chloride three times, and finally once with methyl tert-butyl ether. The resin is then dried in vacuo.



Mass spectrometry (MS) apparatuses Kratos Maldi III and Finnigan LCQ. (M+H)⁺ or M⁺ values are determined.

20


EXAMPLES

Example 1:

- 3 grams (1.62 mmol) of p-nitrophenylcarbonate resin (1) [Novabiochem:
25 0.54 mmol/g loading) is suspended in 30 ml of DMF then 8.1 mmol of propane-1,3-diamine is added at room temperature. The reaction is then heated to 55° and left to stir for two days. The crude reaction is then customary worked up for solid-phase reactions affording the resin bound
30 bis amine (2).




Analogously, by reaction of the p-nitrophenylcarbonate resin (1) with the bis amines of formula IIIa in which Z is absent, R² and R³ are H and n and m has the meanings indicated in Claim 1, excluding propane-1,3-diamine,



the following resin bound bis amines are obtained:

20 methanediamine, resin bound;
ethane-1,2-diamine, resin bound;
butane-1,4-diamine, resin bound;
pentane-1,5-diamine, resin bound and
hexane-1,6-diamine, resin bound.


25 Analogously, by reaction of the p-nitrophenylcarbonate resin (1) with the bis amines of formula IIIb in which Z is phenylene, R² and R³ are H and n and m has the meanings indicated in Claim 1,



the following resin bound bis amines are obtained:

3-aminomethyl-phenylamine, resin bound;
3-aminoethyl-phenylamine, resin bound;
3-aminopropyl-phenylamine, resin bound;

3-aminomethyl-benzylamine, resin (3)



3-aminoethyl-benzylamine, resin bound;

3-aminopropyl-benzylamine, resin bound;

2-[3-(2-aminoethyl)-phenyl]-ethylamine, resin bound;

3-[3-(3-aminopropyl)-phenyl]-propylamine, resin bound;

10 4-aminomethyl-phenylamine, resin bound;

4-aminoethyl-phenylamine, resin bound;

4-aminopropyl-phenylamine, resin bound;

4-aminomethyl-benzylamine, resin bound;

4-aminoethyl-benzylamine, resin bound;

15 4-aminopropyl-benzylamine, resin bound;

2-[4-(2-aminoethyl)-phenyl]-ethylamine, resin bound and

3-[4-(3-aminopropyl)-phenyl]-propylamine, resin bound.

Example 2:

20 1. *Synthesis of Fmoc protected anthranilic acid*


29.15 mmol of anthranilic acid is taken in 100 ml of 1,4 dioxane then 145 mmol of sodium bicarbonate in 20 ml of water is added. Next, 32 mmol of Fmoc-Cl is added and the reaction is left to stir overnight at room temperature. The reaction is then concentrated in vacuo and customary worked up for solution reactions. The resulting solid is triturated in ethyl ether affording the pure product.

25

2. *Coupling of Fmoc protected anthranilic acid to resin*

30 1 gram of resin (2) is suspended in 10 ml of DMF. The reaction is then treated with 1.62 mmol of Fmoc protected anthranilic acid, 1.62 mmol of

HBTU, and 1.62 mmol of triethyl amine. The reaction is then allowed to shake overnight at room temperature. After customary working up, the resin is dried in vacuo affording resin bound anthranilic acid (4).



3. Cleavage of Fmoc protected group


1 gram resin (4) is suspended in 10 ml of 20% piperidine/DMF and shaken for 1.5 hours at room temperature. The reaction is then customary worked up for solid-phase reactions affording the free aniline (5).

15

4. Aldehyde condensation and ring closure


100 mg resin (5) is suspended in 1 ml of dimethyl acetamide then 200 μ l of acetic acid is added followed by the addition of 2.16 mmol of benzaldehyde. The reaction is then heated to 80° for two days. The reaction is then cooled to room temperature and customary worked up for solid-phase reactions affording the resin (6).

20



5. Oxidation to quinazolinone

100 mg resin (6) is suspended in 4 ml solution of 36 mg of DDQ in DMF. Then the reaction is allowed to shake overnight at room temperature. The reaction is then customary worked up for solid-phase reactions affording quinazolinone (7) resin bound.



10


6. Cleavage of the final product 3-(3-aminopropyl)-2-phenyl-3H-quinazolin-4-one

15 100 mg of resin (7) is suspended in 2 ml of a 50% trifluoroacetic acid/methylen chloride solution and shaken for 1.5 hours at room temperature. Customary working up for solid-phase reactions afforded 3-(3-aminopropyl)-2-phenyl-3H-quinazolin-4-one;
MS calc.: 279.3 found: 280.1.

20

Example 3:

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa



cleavage of the Fmoc protecting group and reaction with benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

5 with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-6-chloro-2-phenyl-3H-quinazolin-4-one;

MS calc.: 313.8 found: 314.0;

with R' = 3-CH₃ in formula IIa

10 3-(3-aminopropyl)-6-methyl-2-phenyl-3H-quinazolin-4-one;

MS calc.: 293.4 found: 294.1;

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-7-chloro-2-phenyl-3H-quinazolin-4-one;

15 MS calc.: 313.8 found: 314.0;

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-6-methoxy-2-phenyl-3H-quinazolin-4-one;

MS calc.: 309.4 found: 310.1.

20

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 2-methyl-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

25

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-6-chloro-2-(2-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 327.8 found: 328.1;

30

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-6-methyl-2-(2-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 307.4 found: 308.1;

with R' = 4-Cl in formula IIa

5 3-(3-aminopropyl)-7-chloro-2-(2-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 327.8 found: 328.0;

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-6-methoxy-2-(2-methylphenyl)-3H-quinazolin-4-one;

10 MS calc.: 323.4 found: 324.1;

with R' = H in formula IIa

3-(3-aminopropyl)-2-(2-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 293.4 found: 394.1.

15

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 3-methyl-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

20

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-6-chloro-2-(3-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 327.8;

25

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-6-methyl-2-(3-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 307.4 found: 309.1;

with R' = 4-Cl in formula IIa

30 3-(3-aminopropyl)-7-chloro-2-(3-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 327.8 found: 328.0;

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-6-methoxy-2-(3-methylphenyl)-3H-quinazolin-4-one;

5 MS calc.: 323.4 found: 325.1;

with R' = H in formula IIa

3-(3-aminopropyl)-2-(3-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 293.4 found: 394.1.

10

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 4-methyl-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

15

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-6-chloro-2-(4-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 327.8;

20

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-6-methyl-2-(4-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 307.4 found: 308.1;

with R' = 4-Cl in formula IIa

25 3-(3-aminopropyl)-7-chloro-2-(4-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 327.8;

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-6-methoxy-2-(4-methylphenyl)-3H-quinazolin-4-one;

30 MS calc.: 323.4 found: 324.1;

with R' = H in formula IIa

3-(3-aminopropyl)-2-(4-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 293.4 found: 394.1.

5

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 4-tert-butyl-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

10

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-6-chloro-2-(4-tert-butylphenyl)-3H-quinazolin-4-one;

MS calc.: 369.9 found: 370.1;

15

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-6-methyl-2-(4-tert-butylphenyl)-3H-quinazolin-4-one;

MS calc.: 349.5 found: 350.2;

with R' = 4-Cl in formula IIa

20 3-(3-aminopropyl)-7-chloro-2-(4-tert-butylphenyl)-3H-quinazolin-4-one;

MS calc.: 369.9 found: 370.1;

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-6-methoxy-2-(4-tert-butylphenyl)-3H-quinazolin-4-one;

25

MS calc.: 365.5 found: 366.2;

with R' = H in formula IIa

3-(3-aminopropyl)-2-(4-tert-butylphenyl)-3H-quinazolin-4-one;

MS calc.: 335.5 found: 336.1.

30

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 3-chloro-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

5

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-6-chloro-2-(3-chlorophenyl)-3H-quinazolin-4-one;

MS calc.: 348.2 found: 348.0;

10

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-6-methyl-2-(3-chlorophenyl)-3H-quinazolin-4-one;

MS calc.: 307.4 found: 308.1;

with R' = 4-Cl in formula IIa

15

3-(3-aminopropyl)-7-chloro-2-(3-chlorophenyl)-3H-quinazolin-4-one;

MS calc.: 348.2 found: 348.0;

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-6-methoxy-2-(3-chlorophenyl)-3H-quinazolin-4-one;

20

MS calc.: 343.8 found: 344.1;

with R' = H in formula IIa

3-(3-aminopropyl)-2-(3-chlorophenyl)-3H-quinazolin-4-one;

MS calc.: 313.8 found: 316.1.

25

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 4-methoxy-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

30

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-6-chloro-2-(4-methoxyphenyl)-3H-quinazolin-4-one;

MS calc.: 343.8 found: 344.0;

5 with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-6-methyl-2-(4-methoxyphenyl)-3H-quinazolin-4-one;

MS calc.: 323.4 found: 324.1;

with R' = 4-Cl in formula IIa

10 3-(3-aminopropyl)-7-chloro-2-(4-methoxyphenyl)-3H-quinazolin-4-one;

MS calc.: 343.8 found: 344.0;

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-6-methoxy-2-(4-methoxyphenyl)-3H-quinazolin-4-one;

15 MS calc.: 339.4 found: 340.1;

with R' = H in formula IIa

3-(3-aminopropyl)-2-(4-methoxyphenyl)-3H-quinazolin-4-one;

MS calc.: 309.4 found: 310.1.

20

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 3-methoxy-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

25

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-6-chloro-2-(3-methoxyphenyl)-3H-quinazolin-4-one;

MS calc.: 343.8;

30

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-6-methyl-2-(3-methoxyphenyl)-3H-quinazolin-4-one;

MS calc.: 323.4;

with R' = 4-Cl in formula IIa

5 3-(3-aminopropyl)-7-chloro-2-(3-methoxyphenyl)-3H-quinazolin-4-one;

MS calc.: 343.8;

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-6-methoxy-2-(3-methoxyphenyl)-3H-quinazolin-4-one;

10 MS calc.: 339.4 found: 340.1;

with R' = H in formula IIa


3-(3-aminopropyl)-2-(3-methoxyphenyl)-3H-quinazolin-4-one;

MS calc.: 309.4 found: 310.2.

15

Example 4:

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa



cleavage of the Fmoc protecting group and reaction with 3,4,5-trimethoxybenzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

30

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-6-chloro-2-(3,4,5-trimethoxyphenyl)-3H-quinazolin-4-one;

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-6-methyl-2-(3,4,5-trimethoxyphenyl)-3H-quinazolin-4-one;

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-7-chloro-2-(3,4,5-trimethoxyphenyl)-3H-quinazolin-4-one;

10 with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-6-methoxy-2-(3,4,5-trimethoxyphenyl)-3H-quinazolin-4-one;

with R' = H in formula IIa

15 3-(3-aminopropyl)-2-(3,4,5-trimethoxyphenyl)-3H-quinazolin-4-one.

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 3,4-dimethoxybenzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-6-chloro-2-(3,4-dimethoxyphenyl)-3H-quinazolin-4-one;

25 with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-6-methyl-2-(3,4-dimethoxyphenyl)-3H-quinazolin-4-one;

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-7-chloro-2-(3,4-dimethoxyphenyl)-3H-quinazolin-4-one;

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-6-methoxy-2-(3,4-dimethoxyphenyl)-3H-quinazolin-4-one;

5 with R' = H in formula IIa

3-(3-aminopropyl)-2-(3,4-dimethoxyphenyl)-3H-quinazolin-4-one.

Example 5:

10 Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with [2,2']bithiophenyl-5-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

with R' = 3-Cl in formula IIa

15 3-(3-aminopropyl)-2-[2,2']bithiophenyl-5-yl-6-chloro-3H-quinazolin-4-one;

MS calc.: 401.9 found: 402.0;

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-2-[2,2']bithiophenyl-5-yl-6-methyl-3H-quinazolin-4-one;

20 MS calc.: 381.5 found: 382.1;

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-2-[2,2']bithiophenyl-5-yl-7-chloro-3H-quinazolin-4-one;

MS calc.: 401.9 found: 402.0;

25

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-2-[2,2']bithiophenyl-5-yl-6-methoxy-3H-quinazolin-4-one;

MS calc.: 397.5 found: 398.0;

30 with R' = H in formula IIa

3-(3-aminopropyl)-2-[2,2']bithiophenyl-5-yl-3H-quinazolin-4-one;

MS calc.: 367.5 found: 368.1.

Example 6:

- 5 Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 3-furan-2-yl-propenal, oxidation and cleavage from the solid phase, the following compounds are obtained

- 10 with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-6-chloro-2-(2-furan-2-yl-vinyl)-3H-quinazolin-4-one;

MS calc.: 329.8 found: 330.1;

with R' = 3-CH₃ in formula IIa

- 15 3-(3-aminopropyl)-6-methyl-2-(2-furan-2-yl-vinyl)-3H-quinazolin-4-one;

MS calc.: 309.4 found: 310.2;

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-7-chloro-2-(2-furan-2-yl-vinyl)-3H-quinazolin-4-one;

- 20 MS calc.: 329.8 found: 330.1;

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-6-methoxy-2-(2-furan-2-yl-vinyl)-3H-quinazolin-4-one;

MS calc.: 325.4 found: 326.2;

25

with R' = H in formula IIa

3-(3-aminopropyl)-2-(2-furan-2-yl-vinyl)-3H-quinazolin-4-one;

MS calc.: 295.3 found: 296.2.

30

Example 7:

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with cyclohexanecarbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

5

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-6-chloro-2-cyclohexyl-3H-quinazolin-4-one;

MS calc.: 319.8 found: 320.1;

10

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-6-methyl-2-cyclohexyl-3H-quinazolin-4-one;

MS calc.: 299.4 found: 300.2;

15

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-7-chloro-2-cyclohexyl-3H-quinazolin-4-one;

MS calc.: 319.8 found: 320.1;

20

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-6-methoxy-2-cyclohexyl-3H-quinazolin-4-one;

MS calc.: 315.4 found: 316.2;

25

with R' = H in formula IIa

3-(3-aminopropyl)-2-cyclohexyl-3H-quinazolin-4-one;

MS calc.: 285.4 found: 286.1.

Example 8:

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 3-phenyl-propionaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

30

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-6-chloro-2-phenylethyl-3H-quinazolin-4-one;

MS calc.: 341.8;

5

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-6-methyl-2-phenylethyl-3H-quinazolin-4-one;

MS calc.: 321.4; found: 322.2;

10

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-7-chloro-2-phenylethyl-3H-quinazolin-4-one;

MS calc.: 341.8 found: 342.2;

with R' = 3-OCH₃ in formula IIa

15 3-(3-aminopropyl)-6-methoxy-2-phenylethyl-3H-quinazolin-4-one;

MS calc.: 337.4;

with R' = H in formula IIa

3-(3-aminopropyl)-2-phenylethyl-3H-quinazolin-4-one;

20

MS calc.: 307.4.

Example 9:

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with

25

biphenyl-4-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-2-biphenyl-4-yl-6-chloro-3H-quinazolin-4-one;

30

MS calc.: 389.9 found: 390.1;

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-2-biphenyl-4-yl-6-methyl-3H-quinazolin-4-one;

MS calc.: 369.5 found: 370.1;

5

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-2-biphenyl-4-yl-7-chloro-3H-quinazolin-4-one;

MS calc.: 389.9 found: 390.1;

10

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-2-biphenyl-4-yl-6-methoxy-3H-quinazolin-4-one;

MS calc.: 385.5 found: 386.2;

with R' = H in formula IIa

15 3-(3-aminopropyl)-2-biphenyl-4-yl-3H-quinazolin-4-one;

MS calc.: 355.4 found: 356.1.

Example 10:

20 Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with thiophene-3-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

with R' = 3-Cl in formula IIa

25 3-(3-aminopropyl)-2-thiophenyl-3-yl-6-chloro-3H-quinazolin-4-one;

MS calc.: 319.8 found: 320.1;

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-2-thiophenyl-3-yl-6-methyl-3H-quinazolin-4-one;

30

MS calc.: 299.4 found: 300.1;

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-2-thiophenyl-3-yl-7-chloro-3H-quinazolin-4-one;

MS calc.: 319.8 found: 320.0;

5

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-2-thiophenyl-3-yl-6-methoxy-3H-quinazolin-4-one;

MS calc.: 315.4 found: 316.1;

10

with R' = H in formula IIa

3-(3-aminopropyl)-2-thiophenyl-3-yl-3H-quinazolin-4-one;

MS calc.: 285.4 found: 286.1.

Analogously to example 2, by reaction of resin (2) with a compound of
15 formula IIa; cleavage of the Fmoc protecting group and reaction with
thiophene-2-carbaldehyde, oxidation and cleavage from the solid phase,
the following compounds are obtained

with R' = 3-Cl in formula IIa

20 3-(3-aminopropyl)-2-thiophenyl-2-yl-6-chloro-3H-quinazolin-4-one;

MS calc.: 319.8 found: 320.0;

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-2-thiophenyl-2-yl-6-methyl-3H-quinazolin-4-one;

25

MS calc.: 299.4 found: 300.1;

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-2-thiophenyl-2-yl-7-chloro-3H-quinazolin-4-one;

MS calc.: 319.8 found: 320.0;

30

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-2-thiophenyl-2-yl-6-methoxy-3H-quinazolin-4-one;

MS calc.: 315.4 found: 316.1;

5 with R' = H in formula IIa

3-(3-aminopropyl)-2-thiophenyl-2-yl-3H-quinazolin-4-one;

MS calc.: 285.4 found: 286.1.

Example 11:

10 Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with naphthalene-2-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

15 with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-2-naphthalen-2-yl-6-chloro-3H-quinazolin-4-one;

MS calc.: 363.9 found: 364.1;

with R' = 3-CH₃ in formula IIa

20 3-(3-aminopropyl)-2-naphthalen-2-yl-6-methyl-3H-quinazolin-4-one;

MS calc.: 343.4 found: 344.1;

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-2-naphthalen-2-yl-7-chloro-3H-quinazolin-4-one;

25 MS calc.: 363.9 found: 364.1;

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-2-naphthalen-2-yl-6-methoxy-3H-quinazolin-4-one;

MS calc.: 359.4 found: 360.1;

with R' = H in formula IIa

3-(3-aminopropyl)-2-naphthalen-2-yl-3H-quinazolin-4-one;

MS calc.: 329.4 found: 330.2.

- 5 Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with naphthalene-1-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

10 with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-2-naphthalen-1-yl-6-chloro-3H-quinazolin-4-one;

MS calc.: 363.9;

with R' = 3-CH₃ in formula IIa

15 3-(3-aminopropyl)-2-naphthalen-1-yl-6-methyl-3H-quinazolin-4-one;

MS calc.: 343.4 found: 344.1;

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-2-naphthalen-1-yl-7-chloro-3H-quinazolin-4-one;

20 MS calc.: 363.9 found: 364.0;

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-2-naphthalen-1-yl-6-methoxy-3H-quinazolin-4-one;

MS calc.: 359.4 found: 361.1;

25

with R' = H in formula IIa

3-(3-aminopropyl)-2-naphthalen-1-yl-3H-quinazolin-4-one;

MS calc.: 329.4 found: 330.1.

30

Example 12:

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 3-phenyl-propenal, oxidation and cleavage from the solid phase, the following compounds are obtained

5

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-2-styryl-6-chloro-3H-quinazolin-4-one;

MS calc.: 339.8 found: 340.2;

10

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-2-styryl-6-methyl-3H-quinazolin-4-one;

MS calc.: 319.4 found: 320.2;

with R' = 4-Cl in formula IIa

15

3-(3-aminopropyl)-2-styryl-7-chloro-3H-quinazolin-4-one;

MS calc.: 339.8 found: 340.1;

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-2-styryl-6-methoxy-3H-quinazolin-4-one;

20

MS calc.: 335.4 found: 336.2;

with R' = H in formula IIa

3-(3-aminopropyl)-2-styryl-3H-quinazolin-4-one;

MS calc.: 305.4 found: 306.2.

25

Example 13:

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with benzofuran-5-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

30

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-2-benzofuran-5-yl-6-chloro-3H-quinazolin-4-one;

MS calc.: 353.8 found: 354.1;

5

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-2-benzofuran-5-yl-6-methyl-3H-quinazolin-4-one;

MS calc.: 333.4 found: 334.1;

10

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-2-benzofuran-5-yl-7-chloro-3H-quinazolin-4-one;

MS calc.: 353.8 found: 354.1;

with R' = 3-OCH₃ in formula IIa

15

3-(3-aminopropyl)-2-benzofuran-5-yl-6-methoxy-3H-quinazolin-4-one;

MS calc.: 349.4 found: 350.1;

with R' = H in formula IIa

3-(3-aminopropyl)-2-benzofuran-5-yl-3H-quinazolin-4-one;

20

MS calc.: 319.4 found: 320.1.

Example 14:

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 3-(4-dimethylamino-phenyl)-propenal, oxidation and cleavage from the solid phase, the following compounds are obtained

25

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-2-[2-(4-dimethylamino-phenyl)-vinyl]-6-chloro-3H-

30

quinazolin-4-one;

MS calc.: 382.9 ;

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-2-[2-(4-dimethylamino-phenyl)-vinyl]-6-methyl-3H-
5 quinazolin-4-one;

MS calc.: 362.5;

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-2-[2-(4-dimethylamino-phenyl)-vinyl]-7-chloro-3H-
10 quinazolin-4-one;

MS calc.: 382.9;

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-2-[2-(4-dimethylamino-phenyl)-vinyl]-6-methoxy-3H-
15 quinazolin-4-one;

MS calc.: 378.5;

with R' = H in formula IIa

3-(3-aminopropyl)-2-[2-(4-dimethylamino-phenyl)-vinyl]-3H-quinazolin-4-
20 one;

MS calc.: 348.5.

Analogously to example 2, by reaction of resin (2) with a compound of
formula IIa, cleavage of the Fmoc protecting group and reaction with 3-(2,5-
25 dimethoxy-phenyl)-propenal, oxidation and cleavage from the solid phase,
the following compounds are obtained

with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-2-[2-(2,5-dimethoxy-phenyl)-vinyl]-6-chloro-3H-
30 quinazolin-4-one;

with R' = 3-CH₃ in formula IIa

3-(3-aminopropyl)-2-[2-(2,5-dimethoxy-phenyl)-vinyl]-6-methyl-3H-quinazolin-4-one;

5

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-2-[2-(2,5-dimethoxy-phenyl)-vinyl]-7-chloro-3H-quinazolin-4-one;

10

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-2-[2-(2,5-dimethoxy-phenyl)-vinyl]-6-methoxy-3H-quinazolin-4-one;

with R' = H in formula IIa

15 3-(3-aminopropyl)-2-[2-(2,5-dimethoxy-phenyl)-vinyl]-3H-quinazolin-4-one.

Example 15:

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 4-bromo-benzaldehyde, Suzuki-reaction with 2,4-dimethoxyphenyl boronic acid as indicated afterwards, oxidation and cleavage from the solid phase, the following compounds are obtained

20

with R' = 3-Cl in formula IIa

25 3-(3-aminopropyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-6-chloro-3H-quinazolin-4-one;

with R' = 3-CH₃ in formula IIa

30 3-(3-aminopropyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-6-methyl-3H-quinazolin-4-one;

with R' = 4-Cl in formula IIa

3-(3-aminopropyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-7-chloro-3H-quinazolin-4-one;

5

with R' = 3-OCH₃ in formula IIa

3-(3-aminopropyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-6-methoxy-3H-quinazolin-4-one;

10

with R' = H in formula IIa

3-(3-aminopropyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-3H-quinazolin-4-one.

Suzuki reaction according to G.C. Fu et al., Angew. Chem. 1998, 110, 3586-3587:

15

1 gram of resin bound 3-(3-aminomethyl-cyclohexylmethyl)-2-(4-bromophenyl)-3H-quinazolin-4-one is suspended in 10 ml of 1,4-dioxane. The reaction is then treated with 1.62 mmol Cs₂CO₃, 1.62 mmol of 2,4-dimethoxyphenyl boronic acid and 10 mol% ([Pd₂(dba)₃] + P(tert-Bu)₃). The reaction is then allowed to shake at 80° until conversion is complete. After cooling the reaction mixture, it is worked up as is customary.

20

Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 4-bromo-benzaldehyde, Suzuki-reaction with 3,5-dimethoxyphenyl boronic acid as indicated afterwards, oxidation and cleavage from the solid phase, the following compounds are obtained

25

with R' = 3-Cl in formula IIa

30

3-(3-aminopropyl)-2-(3',5'-dimethoxy-biphenyl-4-yl)-6-chloro-3H-quinazolin-4-one;

with R' = 3-CH₃ in formula IIa

5 3-(3-aminopropyl)-2-(3',5'-dimethoxy-biphenyl-4-yl)-6-methyl-3H-quinazolin-4-one;

with R' = 4-Cl in formula IIa

10 3-(3-aminopropyl)-2-(3',5'-dimethoxy-biphenyl-4-yl)-7-chloro-3H-quinazolin-4-one;

with R' = 3-OCH₃ in formula IIa

15 3-(3-aminopropyl)-2-(3',5'-dimethoxy-biphenyl-4-yl)-6-methoxy-3H-quinazolin-4-one;

with R' = H in formula IIa

3-(3-aminopropyl)-2-(3',5'-dimethoxy-biphenyl-4-yl)-3H-quinazolin-4-one.

20 Analogously to example 2, by reaction of resin (2) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 5-bromo-thiophenyl-2-carbaldehyde, Suzuki-reaction with 3,4-dimethoxyphenyl boronic acid as indicated afterwards, oxidation and cleavage from the solid phase, the following compounds are obtained

25 with R' = 3-Cl in formula IIa

3-(3-aminopropyl)-2-[5-(2,4-dimethoxy-phenyl)-thiophen-2-yl]-6-chloro-3H-quinazolin-4-one;

with R' = 3-CH₃ in formula IIa

30

3-(3-aminopropyl)-2-[5-(2,4-dimethoxy-phenyl)-thiophen-2-yl]-6-methyl-3H-quinazolin-4-one;

with R' = 4-Cl in formula IIa

5 3-(3-aminopropyl)-2-[5-(2,4-dimethoxy-phenyl)-thiophen-2-yl]-7-chloro-3H-quinazolin-4-one;

with R' = 3-OCH₃ in formula IIa

10 3-(3-aminopropyl)-2-[5-(2,4-dimethoxy-phenyl)-thiophen-2-yl]-6-methoxy-3H-quinazolin-4-one;

with R' = H in formula IIa

3-(3-aminopropyl)-2-[5-(2,4-dimethoxy-phenyl)-thiophen-2-yl]-3H-quinazolin-4-one.

15

Example 16:

1. Synthesis of Fmoc protected anthranilic acid


29.15 mmol of anthranilic acid is taken in 100 ml of 1,4 dioxane then 145 mmol of sodium bicarbonate in 20 ml of water is added. Next, 32 mmol of Fmoc-Cl is added and the reaction is left to stir overnight at room temperature. The reaction is then concentrated in vacuo and customary worked up for solution reactions. The resulting solid is triturated in ethyl ether affording the pure product.

25 2. Coupling of Fmoc protected anthranilic acid to resin

1 gram of resin (3) is suspended in 10 ml of DMF. The reaction is then treated with 1.62 mmol of Fmoc protected anthranilic acid, 1.62 mmol of HBTU, and 1.62 mmol of triethyl amine. The reaction is then allowed to shake overnight at room temperature. After customary working up, the resin is dried in vacuo affording resin bound anthranilic acid (8).

30

5



3. Cleavage of Fmoc protected group

10


1 gram resin (8) is suspended in 10 ml of 20% piperidine/DMF and shaken for 1.5 hours at room temperature. The reaction is then customary worked up for solid-phase reactions affording the free aniline (9).

4. Aldehyde condensation and ring closure

15

100 mg resin (9) is suspended in 1 ml of dimethyl acetamide then 200 μ l of acetic acid is added followed by the addition of 2.16 mmol of benzaldehyde. The reaction is then heated to 80° for two days. The reaction is then cooled to room temperature and customary worked up for solid-phase reactions affording the resin (10).

20




25

5. Oxidation to quinazolinone

30

100 mg resin (10) is suspended in 4 ml solution of 36 mg of DDQ in DMF. Then the reaction is allowed to shake overnight at room temperature. The reaction is then customary worked up for solid-phase reactions affording quinazolinone (11) resin bound.




6. Cleavage of the final product 3-(3-aminomethyl-benzyl)-2-phenyl-3H-quinazolin-4-one

10 100 mg of resin (11) is suspended in 2 ml of a 50% trifluoroacetic acid/methylen chloride solution and shaken for 1.5 hours at room temperature. Customary working up for solid-phase reactions afforded 3-(3-aminomethyl-benzyl)-2-phenyl-3H-quinazolin-4-one;

MS calc.: 341.4 found: 342.1.

15 Example 17:

Analogously to example 16, by reaction of resin (3) with a compound of formula IIa



25 cleavage of the Fmoc protecting group and reaction with benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

30 with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-6-chloro-2-phenyl-3H-quinazolin-4-one;

MS calc.: 375.9 found: 376.1;

with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methyl-2-phenyl-3H-quinazolin-4-one;

5 MS calc.: 355.4 found: 356.1;

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-7-chloro-2-phenyl-3H-quinazolin-4-one;

MS calc.: 375.9;

10

with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methoxy-2-phenyl-3H-quinazolin-4-one;

MS calc.: 371.4 found: 372.2.

15 Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 2-methyl-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

20 with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-6-chloro-2-(2-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 389.9 found: 390.1;

25 with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methyl-2-(2-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 369.5 found: 370.2;

30 with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-7-chloro-2-(2-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 389.9 found: 390.1;

5 with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methoxy-2-(2-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 385.5 found: 386.2;

10 with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-(2-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 355.4 found: 356.2.

15 Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 3-methyl-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

with R' = 3-Cl in formula IIa

20 3-(3-aminomethyl-benzyl)-6-chloro-2-(3-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 389.9 found: 390.1;

with R' = 3-CH₃ in formula IIa

25 3-(3-aminomethyl-benzyl)-6-methyl-2-(3-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 369.5 found: 370.2;

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-7-chloro-2-(3-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 389.9 found: 390.1;

5 with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methoxy-2-(3-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 385.5 found: 386.2;

10 with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-(3-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 355.4 found: 356.1.

15 Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 4-methyl-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

with R' = 3-Cl in formula IIa

20 3-(3-aminomethyl-benzyl)-6-chloro-2-(4-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 389.9 found: 390.1;

with R' = 3-CH₃ in formula IIa

25 3-(3-aminomethyl-benzyl)-6-methyl-2-(4-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 369.5 found: 370.2;

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-7-chloro-2-(4-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 389.9 found: 390.1;

5 with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methoxy-2-(4-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 385.5 found: 386.2;

10 with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-(4-methylphenyl)-3H-quinazolin-4-one;

MS calc.: 355.4 found: 356.2.

15 Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 4-tert-butyl-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

with R' = 3-Cl in formula IIa

20 3-(3-aminomethyl-benzyl)-6-chloro-2-(4-tert-butylphenyl)-3H-quinazolin-4-one;

MS calc.: 432.0 found: 432.2;

with R' = 3-CH₃ in formula IIa

25 3-(3-aminomethyl-benzyl)-6-methyl-2-(4-tert-butylphenyl)-3H-quinazolin-4-one;

MS calc.: 411.6 found: 412.2;

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-7-chloro-2-(4-tert-butylphenyl)-3H-quinazolin-4-one;
MS calc.: 432.0 found: 432.2;

5 with R' = 3-OCH₃ in formula IIa
3-(3-aminomethyl-benzyl)-6-methoxy-2-(4-tert-butylphenyl)-3H-quinazolin-4-one;
MS calc.: 427.6 found: 428.2;

10 with R' = H in formula IIa
3-(3-aminomethyl-benzyl)-2-(4-tert-butylphenyl)-3H-quinazolin-4-one;
MS calc.: 397.5 found: 398.2.

15 Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc-protecting group and reaction with 3-chloro-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

20 with R' = 3-Cl in formula IIa
3-(3-aminomethyl-benzyl)-6-chloro-2-(3-chlorophenyl)-3H-quinazolin-4-one;
MS calc.: 410.3 found: 410.1;

25 with R' = 3-CH₃ in formula IIa
3-(3-aminomethyl-benzyl)-6-methyl-2-(3-chlorophenyl)-3H-quinazolin-4-one;
MS calc.: 389.9 found: 390.1;

30 with R' = 4-Cl in formula IIa
3-(3-aminomethyl-benzyl)-7-chloro-2-(3-chlorophenyl)-3H-quinazolin-4-one;
MS calc.: 410.3 found: 410.0;

with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methoxy-2-(3-chlorophenyl)-3H-quinazolin-4-one;

5 MS calc.: 405.9 found: 406.1;

with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-(3-chlorophenyl)-3H-quinazolin-4-one;

10 MS calc.: 375.9 found: 376.1.

Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 4-methoxy-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

15

with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-6-chloro-2-(4-methoxyphenyl)-3H-quinazolin-4-one;

20 MS calc.: 405.9 found: 406.1;

20

with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methyl-2-(4-methoxyphenyl)-3H-quinazolin-4-one;

25 MS calc.: 385.5 found: 386.2;

25

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-7-chloro-2-(4-methoxyphenyl)-3H-quinazolin-4-one;

30 MS calc.: 405.9 found: 406.1;

30

with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methoxy-2-(4-methoxyphenyl)-3H-quinazolin-4-one;

MS calc.: 401.5 found: 402.1;

5

with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-(4-methoxyphenyl)-3H-quinazolin-4-one;

MS calc.: 371.4 found: 372.2.

- 10 Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 3-methoxy-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

15 with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-6-chloro-2-(3-methoxyphenyl)-3H-quinazolin-4-one;

MS calc.: 405.9;

20 with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methyl-2-(3-methoxyphenyl)-3H-quinazolin-4-one;

MS calc.: 385.5;

25 with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-7-chloro-2-(3-methoxyphenyl)-3H-quinazolin-4-one;

MS calc.: 405.9;

30 with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methoxy-2-(3-methoxyphenyl)-3H-quinazolin-4-one;

MS calc.: 401.5;


5 with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-(3-methoxyphenyl)-3H-quinazolin-4-one;

MS calc.: 371.4.

Example 18:

10 Analogously to example 16, by reaction of resin (3) with a compound of formula IIa



15

20 cleavage of the Fmoc protecting group and reaction with 3,4,5-trimethoxybenzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-6-chloro-2-(3,4,5-trimethoxyphenyl)-3H-quinazolin-4-one;

25

with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methyl-2-(3,4,5-trimethoxyphenyl)-3H-quinazolin-4-one;

30

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-7-chloro-2-(3,4,5-trimethoxyphenyl)-3H-quinazolin-4-one;

5 with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methoxy-2-(3,4,5-trimethoxyphenyl)-3H-quinazolin-4-one;

with R' = H in formula IIa

10 3-(3-aminomethyl-benzyl)-2-(3,4,5-trimethoxyphenyl)-3H-quinazolin-4-one.

Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 3,4-dimethoxybenzaldehyde, oxidation and cleavage from the solid phase, the

15 following compounds are obtained

with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-6-chloro-2-(3,4-dimethoxyphenyl)-3H-quinazolin-4-one;

20

with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methyl-2-(3,4-dimethoxyphenyl)-3H-quinazolin-4-one;

25

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-7-chloro-2-(3,4-dimethoxyphenyl)-3H-quinazolin-4-one;

with R' = 3-OCH₃ in formula IIa

30

3-(3-aminomethyl-benzyl)-6-methoxy-2-(3,4-dimethoxyphenyl)-3H-quinazolin-4-one;

with R' = H in formula IIa

5 3-(3-aminomethyl-benzyl)-2-(3,4-dimethoxyphenyl)-3H-quinazolin-4-one.

Example 19:

Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with
10 [2,2']bithiophenyl-5-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

with R' = 3-Cl in formula IIa

15 3-(3-aminomethyl-benzyl)-2-[2,2']bithiophenyl-5-yl-6-chloro-3H-quinazolin-4-one;

MS calc.: 464.0 found: 464.0;

with R' = 3-CH₃ in formula IIa

20 3-(3-aminomethyl-benzyl)-2-[2,2']bithiophenyl-5-yl-6-methyl-3H-quinazolin-4-one;

MS calc.: 443.6 found: 444.1;

with R' = 4-Cl in formula IIa

25 3-(3-aminomethyl-benzyl)-2-[2,2']bithiophenyl-5-yl-7-chloro-3H-quinazolin-4-one;

MS calc.: 464.0 found: 464.0;

with R' = 3-OCH₃ in formula IIa

30 3-(3-aminomethyl-benzyl)-2-[2,2']bithiophenyl-5-yl-6-methoxy-3H-quinazolin-4-one;

MS calc.: 459.6 found: 460.1;

with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-[2,2']bithiophenyl-5-yl-3H-quinazolin-4-one;

5 MS calc.: 429.6 found: 430.1.

Example 20:

Analogously to example 16, by reaction of resin (3) with a compound of
formula IIa, cleavage of the Fmoc protecting group and reaction with 3-
10 furan-2-yl-propenal, oxidation and cleavage from the solid phase, the
following compounds are obtained

with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-6-chloro-2-(2-furan-2-yl-vinyl)-3H-quinazolin-4-
15 one;

MS calc.: 391.9 found: 392.2;

with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methyl-2-(2-furan-2-yl-vinyl)-3H-quinazolin-4-
20 one;

MS calc.: 371.4 found: 372.2;

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-7-chloro-2-(2-furan-2-yl-vinyl)-3H-quinazolin-4-
25 one;

MS calc.: 391.9 found: 392.1;

with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methoxy-2-(2-furan-2-yl-vinyl)-3H-quinazolin-4-
30 one;

MS calc.: 387.4 found: 388.2;

with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-(2-furan-2-yl-vinyl)-3H-quinazolin-4-one;

5 MS calc.: 357.4 found: 358.2.

Example 21:

Analogously to example 16, by reaction of resin (3) with a compound of
formula IIa, cleavage of the Fmoc protecting group and reaction with
10 cyclohexanecarbaldehyde, oxidation and cleavage from the solid phase,
the following compounds are obtained

with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-6-chloro-2-cyclohexyl-3H-quinazolin-4-one;

15 MS calc.: 381.9 found: 382.2;

with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methyl-2-cyclohexyl-3H-quinazolin-4-one;

MS calc.: 361.5 found: 362.3;

20

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-7-chloro-2-cyclohexyl-3H-quinazolin-4-one;

MS calc.: 381.9 found: 382.2;

25 with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methoxy-2-cyclohexyl-3H-quinazolin-4-one;

MS calc.: 377.5 found: 378.2;

with R' = H in formula IIa

30 3-(3-aminomethyl-benzyl)-2-cyclohexyl-3H-quinazolin-4-one;

MS calc.: 347.5 found: 348.2.

Example 22:

5 Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 3-phenyl-propionaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

with R' = 3-Cl in formula IIa

10 3-(3-aminomethyl-benzyl)-6-chloro-2-phenylethyl-3H-quinazolin-4-one;

MS calc.: 403.9 found: 404.2;

with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methyl-2-phenylethyl-3H-quinazolin-4-one;

15 MS calc.: 383.5 found: 384.3;

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-7-chloro-2-phenylethyl-3H-quinazolin-4-one;

MS calc.: 403.9 found: 404.2;

20

with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-6-methoxy-2-phenylethyl-3H-quinazolin-4-one;

MS calc.: 399.5 found: 400.3;

25

with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-phenylethyl-3H-quinazolin-4-one;

MS calc.: 369.5 found: 370.3.

Example 23:

30

Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with biphenyl-4-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

5

with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-biphenyl-4-yl-6-chloro-3H-quinazolin-4-one;

MS calc.: 452.0 found: 452.1;

10

with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-biphenyl-4-yl-6-methyl-3H-quinazolin-4-one;

MS calc.: 431.5 found: 432.2;

with R' = 4-Cl in formula IIa

15

3-(3-aminomethyl-benzyl)-2-biphenyl-4-yl-7-chloro-3H-quinazolin-4-one;

MS calc.: 452.0 found: 452.1;

with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-biphenyl-4-yl-6-methoxy-3H-quinazolin-4-one;

20

MS calc.: 447.5 found: 448.1;

with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-biphenyl-4-yl-3H-quinazolin-4-one;

MS calc.: 417.5 found: 418.1.

25

Example 24:

Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with thiophene-3-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

30

with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-thiophenyl-3-yl-6-chloro-3H-quinazolin-4-one;

MS calc.: 381.9 found: 382.1;

5

with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-thiophenyl-3-yl-6-methyl-3H-quinazolin-4-one;

MS calc.: 361.5 found: 362.2;

10

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-thiophenyl-3-yl-7-chloro-3H-quinazolin-4-one;

MS calc.: 381.9 found: 382.1;

with R' = 3-OCH₃ in formula IIa

15 3-(3-aminomethyl-benzyl)-2-thiophenyl-3-yl-6-methoxy-3H-quinazolin-4-one;

MS calc.: 377.5;

with R' = H in formula IIa

20 3-(3-aminomethyl-benzyl)-2-thiophenyl-3-yl-3H-quinazolin-4-one;

MS calc.: 347.4 found: 348.2.

Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with
25 thiophene-2-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-thiophenyl-2-yl-6-chloro-3H-quinazolin-4-one;

30 MS calc.: 381.9 found: 382.0;

with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-thiophenyl-2-yl-6-methyl-3H-quinazolin-4-one;

MS calc.: 361.5 found: 362.1;

5

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-thiophenyl-2-yl-7-chloro-3H-quinazolin-4-one;

MS calc.: 381.9 found: 382.0;

10

with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-thiophenyl-2-yl-6-methoxy-3H-quinazolin-4-one;

MS calc.: 377.5 found: 378.1;

15

with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-thiophenyl-2-yl-3H-quinazolin-4-one;

MS calc.: 347.4 found: 348.1.

Example 25:

20

Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with naphthalene-2-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

25

with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-naphthalen-2-yl-6-chloro-3H-quinazolin-4-one;

MS calc.: 425.9 found: 426.1;

with R' = 3-CH₃ in formula IIa

30

3-(3-aminomethyl-benzyl)-2-naphthalen-2-yl-6-methyl-3H-quinazolin-4-one;

MS calc.: 405.5 found: 406.1;

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-naphthalen-2-yl-7-chloro-3H-quinazolin-4-one;

5 MS calc.: 425.9 found: 426.1;

with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-naphthalen-2-yl-6-methoxy-3H-quinazolin-4-one;

10 MS calc.: 421.5 found: 422.2;

with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-naphthalen-2-yl-3H-quinazolin-4-one;

MS calc.: 391.5 found: 392.2.

15

Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with naphthalene-1-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

20

with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-naphthalen-1-yl-6-chloro-3H-quinazolin-4-one;

MS calc.: 425.9 found: 426.1;

25 with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-naphthalen-1-yl-6-methyl-3H-quinazolin-4-one;

MS calc.: 405.5 found: 406.1;

with R' = 4-Cl in formula IIa

30 3-(3-aminomethyl-benzyl)-2-naphthalen-1-yl-7-chloro-3H-quinazolin-4-one;

MS calc.: 425.9 found: 426.1;

with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-naphthalen-1-yl-6-methoxy-3H-quinazolin-4-one;

5

MS calc.: 421.5 found: 422.1;

with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-naphthalen-1-yl-3H-quinazolin-4-one;

10

MS calc.: 391.5 found: 393.2.

Example 26:

15 Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 3-phenyl-propenal, oxidation and cleavage from the solid phase, the following compounds are obtained

20 with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-styryl-6-chloro-3H-quinazolin-4-one;

MS calc.: 401.9 found: 402.2;

with R' = 3-CH₃ in formula IIa

25 3-(3-aminomethyl-benzyl)-2-styryl-6-methyl-3H-quinazolin-4-one;

MS calc.: 381.5 found: 382.2;

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-styryl-7-chloro-3H-quinazolin-4-one;

30

MS calc.: 401.9 found: 403.2;

with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-styryl-6-methoxy-3H-quinazolin-4-one;

MS calc.: 397.5 found: 398.2;

5

with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-styryl-3H-quinazolin-4-one;

MS calc.: 367.5 found: 368.2.

10 Example 27:

Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with benzofuran-5-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained

15

with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-benzofuran-5-yl-6-chloro-3H-quinazolin-4-one;

MS calc.: 415.9 found: 416.1;

20

with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-benzofuran-5-yl-6-methyl-3H-quinazolin-4-one;

MS calc.: 395.5 found: 396.1;

with R' = 4-Cl in formula IIa

25

3-(3-aminomethyl-benzyl)-2-benzofuran-5-yl-7-chloro-3H-quinazolin-4-one;

MS calc.: 415.9 found: 416.1;

with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-benzofuran-5-yl-6-methoxy-3H-quinazolin-4-one;

30

MS calc.: 411.5 found: 412.2;

with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-benzofuran-5-yl-3H-quinazolin-4-one;

5 MS calc.: 381.4 found: 382.1.

Example 28:

Analogously to example 16, by reaction of resin (3) with a compound of
formula IIa, cleavage of the Fmoc protecting group and reaction with 3-(4-
10 dimethylamino-phenyl)-propenal, oxidation and cleavage from the solid
phase, the following compounds are obtained

with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-[2-(4-dimethylamino-phenyl)-vinyl]-6-chloro-3H-
15 quinazolin-4-one;

MS calc.: 445.0 found: 445.2;

with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-[2-(4-dimethylamino-phenyl)-vinyl]-6-methyl-
20 3H-quinazolin-4-one;

MS calc.: 424.6 ;

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-[2-(4-dimethylamino-phenyl)-vinyl]-7-chloro-3H-
25 quinazolin-4-one;

MS calc.: 445.0 found: 445.1;

with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-[2-(4-dimethylamino-phenyl)-vinyl]-6-methoxy-
30 3H-quinazolin-4-one;

MS calc.: 440.5;

with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-[2-(4-dimethylamino-phenyl)-vinyl]-3H-
5 quinazolin-4-one;

MS calc.: 410.5.

Analogously to example 16, by reaction of resin (3) with a compound of
formula IIa, cleavage of the Fmoc protecting group and reaction with 3-(2,5-
10 dimethoxy-phenyl)-propenal, oxidation and cleavage from the solid phase,
the following compounds are obtained

with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-[2-(2,5-dimethoxy-phenyl)-vinyl]-6-chloro-3H-
15 quinazolin-4-one;

with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-[2-(2,5-dimethoxy-phenyl)-vinyl]-6-methyl-3H-
20 quinazolin-4-one;

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-[2-(2,5-dimethoxy-phenyl)-vinyl]-7-chloro-3H-
quinazolin-4-one;

25 with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-[2-(2,5-dimethoxy-phenyl)-vinyl]-6-methoxy-
3H-quinazolin-4-one;

with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-[2-(2,5-dimethoxy-phenyl)-vinyl]-3H-quinazolin-4-one.

Example 29:

5 Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 4-bromo-benzaldehyde, Suzuki-reaction with 2,4-dimethoxyphenyl boronic acid as indicated afterwards, oxidation and cleavage from the solid phase, the following compounds are obtained

10

with R' = 3-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-6-chloro-3H-quinazolin-4-one;

15

with R' = 3-CH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-6-methyl-3H-quinazolin-4-one;

20

with R' = 4-Cl in formula IIa

3-(3-aminomethyl-benzyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-7-chloro-3H-quinazolin-4-one;

25

with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-6-methoxy-3H-quinazolin-4-one;

with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-3H-quinazolin-4-one.

30

Suzuki reaction according to G.C. Fu et al., Angew. Chem. 1998, 110, 3586-3587:

1 gram of resin bound 3-(3-aminomethyl-cyclohexylmethyl)-2-(4-
5 bromophenyl)-3H-quinazolin-4-one is suspended in 10 ml of 1,4-dioxane.
The reaction is then treated with 1.62 mmol Cs_2CO_3 , 1.62 mmol of 2,4-
dimethoxyphenyl boronic acid and 10 mol% ($[\text{Pd}_2(\text{dba})_3] + \text{P}(\text{tert-Bu})_3$). The
reaction is then allowed to shake at 80° until conversion is complete. After
cooling the reaction mixture, it is worked up as is customary.

10

Analogously to example 16, by reaction of resin (3) with a compound of
formula IIa, cleavage of the Fmoc protecting group and reaction with 4-
bromo-benzaldehyde, Suzuki-reaction with 3,5-dimethoxyphenyl boronic
acid as indicated afterwards, oxidation and cleavage from the solid phase,
15 the following compounds are obtained

with $\text{R}' = 3\text{-Cl}$ in formula IIa

3-(3-aminomethyl-benzyl)-2-(3',5'-dimethoxy-biphenyl-4-yl)-6-chloro-3H-
quinazolin-4-one;

20

with $\text{R}' = 3\text{-CH}_3$ in formula IIa

3-(3-aminomethyl-benzyl)-2-(3',5'-dimethoxy-biphenyl-4-yl)-6-methyl-3H-
quinazolin-4-one;

25

with $\text{R}' = 4\text{-Cl}$ in formula IIa

3-(3-aminomethyl-benzyl)-2-(3',5'-dimethoxy-biphenyl-4-yl)-7-chloro-3H-
quinazolin-4-one;

with $\text{R}' = 3\text{-OCH}_3$ in formula IIa

30

3-(3-aminomethyl-benzyl)-2-(3',5'-dimethoxy-biphenyl-4-yl)-6-methoxy-3H-quinazolin-4-one;

with R' = H in formula IIa

5 3-(3-aminomethyl-benzyl)-2-(3',5'-dimethoxy-biphenyl-4-yl)-3H-quinazolin-4-one.

Analogously to example 16, by reaction of resin (3) with a compound of formula IIa, cleavage of the Fmoc protecting group and reaction with 5-bromo-thiophenyl-2-carbaldehyde, Suzuki-reaction with 3,4-dimethoxyphenyl boronic acid as indicated afterwards, oxidation and cleavage from the solid phase, the following compounds are obtained

with R' = 3-Cl in formula IIa

15 3-(3-aminomethyl-benzyl)-2-[5-(2,4-dimethoxy-phenyl)-thiophen-2-yl]-6-chloro-3H-quinazolin-4-one;

with R' = 3-CH₃ in formula IIa

20 3-(3-aminomethyl-benzyl)-2-[5-(2,4-dimethoxy-phenyl)-thiophen-2-yl]-6-methyl-3H-quinazolin-4-one;

with R' = 4-Cl in formula IIa

25 3-(3-aminomethyl-benzyl)-2-[5-(2,4-dimethoxy-phenyl)-thiophen-2-yl]-7-chloro-3H-quinazolin-4-one;

with R' = 3-OCH₃ in formula IIa

3-(3-aminomethyl-benzyl)-2-[5-(2,4-dimethoxy-phenyl)-thiophen-2-yl]-6-methoxy-3H-quinazolin-4-one;

30 with R' = H in formula IIa

3-(3-aminomethyl-benzyl)-2-[5-(2,4-dimethoxy-phenyl)-thiophen-2-yl]-3H-quinazolin-4-one.

The following examples relate to pharmaceutical preparations:

5

Example A: Injection vials

A solution of 100 g of an active compound of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water using 2N hydrochloric acid, sterile-filtered, dispensed into injection vials, lyophilized under sterile conditions and aseptically sealed. Each injection vial contains 5 mg of active compound.

10

15

Example B: Suppositories

A mixture of 20 g of an active compound of the formula I is melted with 100 g of soya lecithin and 1400 g of cocoa butter, poured into moulds and allowed to cool. Each suppository contains 20 mg of active compound.

20

Example C: Solution

A solution is prepared from 1 g of an active compound of the formula I, 9.38 g of $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$, 28.48 g of $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$ and 0.1 g of benzalkonium chloride in 940 ml of double-distilled water. The mixture is adjusted to pH 6.8, made up to 1 l and sterilized by irradiation. This solution can be used in the form of eye drops.

25

Example D: Ointment

500 mg of an active compound of the formula I is mixed with 99.5 g of petroleum jelly under aseptic conditions.

30

Example E: Tablets

A mixture of 1 kg of active compound of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 g of talc and 0.1 kg of magnesium stearate is compressed in a customary manner to give tablets such that each tablet contains 10 mg of active compound.

5

Example F: Coated tablets

Analogously to Example E, tablets are pressed which are then coated with a coating of sucrose, potato starch, talc, tragacanth and colourant in a customary manner.

10

Example G: Capsules

2 kg of active compound of the formula I are dispensed into hard gelatin capsules in a customary manner such that each capsule contains 20 mg of the active compound.

15

Example H: Ampoules

A solution of 1 kg of active compound of the formula I in 60 ml. of double-distilled water is sterile-filtered, dispensed into ampoules, lyophilized under sterile conditions and aseptically sealed. Each ampoule contains 10 mg of active compound.


20

25

30

What is claimed is:

1. Compounds of the formula I



in which

10 R and R¹ are independently of each other H, A, OH, OA, OCH₂-Ar, Hal, NH₂, NHA, NA₂, NO₂, CN, C(O)R², CONH₂, CONHA, CONA₂, COOH, COOA or SO₂A,

R² and R³ are independently of each other H, A, -C(=NH)-NH₂ or solid phase,

R⁴ is Ar, cycloalkyl, phenylalkyl or Het,

15 Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms,

Z may be absent and, if present, is phenylene,

A is unbranched or branched alkyl having 1 to 6 carbon atoms,

20 Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,

25 Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A, Hal, OH, OA, CF₃, OCF₃, NH₂, NHA, NA₂, COOH, COOA, phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, 30 NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂ or thiophenyl

which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂

Hal is F, Cl, Br or I,

5 n is 1, 2 or 3,

m is 0, 1, 2 or 3,

with the proviso if Z and Y are absent and R⁴ is phenyl or 4-methoxyphenyl, then R is not H or 6-Cl, R¹ is not H or 8-Cl, R² is not H, methyl or ethyl, R³ is not H, methyl or ethyl and the sum of n and m (= n+m) is not 2 or 3,

10

if Z and Y are absent, R⁴ is phenyl or 4-methoxyphenyl, R, R¹, R² and R³ are H, then the sum of n and m (= n+m) is not 2 or 3,

if Y is vinyl, R⁴ is phenyl, Z is absent, n is 1, m is 1 and R² and R³ are ethyl, then R or R¹ is not NH₂,

15

if Z is absent, Y is absent or vinyl, R⁴ is phenyl, phenylalkyl, alkoxyphenyl or pyridyl, R is H and R¹ is NH₂, then R² and R³ are not A, and if Z and Y are absent, then R⁴ is not phenylalkyl and their pharmaceutically tolerable salts and solvates.

20

2. Compounds of the formula I according to Claim 1

a) 3-(3-aminomethyl-benzyl)-2-[2,2']bithiophenyl-5-yl-6-methoxy-3H-quinazolin-4-one,

b) 3-(3-aminomethyl-propyl)-2-[2,2']bithiophenyl-5-yl-6-chloro-3H-quinazolin-4-one,


25

c) 3-(3-aminomethyl-propyl)-2-[2,2']bithiophenyl-5-yl-7-chloro-3H-quinazolin-4-one

and their physiologically acceptable salts and solvates.

3. Process for the preparation of the compounds of the formula I

30



- 5 in which
- R and R¹ are independently of each other H, A, OH, OA, OCH₂-Ar, Hal, NH₂, NHA, NA₂, NO₂, CN, C(O)R², CONH₂, CONHA, CONA₂, COOH, COOA or SO₂A,
- 10 R² and R³ are independently of each other H, A, -C(=NH)-NH₂ or solid phase,
- R⁴ is Ar, cycloalkyl, phenylalkyl or Het,
- Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms,
- Z may be absent and, if present, is phenylene,
- 15 A is unbranched or branched alkyl having 1 to 6 carbon atoms,
- Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,
- 20 Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A, Hal, OH, OA, CF₃, OCF₃, NH₂, NHA, NA₂, COOH, COOA,
- 25 phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂ or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂,
- 30 NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂

Hal is F, Cl, Br or I,

n is 1, 2 or 3,

m is 0, 1, 2 or 3,

with the proviso if Z and Y are absent and R⁴ is phenyl or 4-

5 methoxyphenyl, then R is not H or 6-Cl, R¹ is not H or 8-Cl, R² is not H, methyl or ethyl, R³ is not H, methyl or ethyl and the sum of n and m (= n+m) is not 2 or 3,

if Z and Y are absent, R⁴ is phenyl or 4-methoxyphenyl, R, R¹, R² and R³ are H, then the sum of n and m (= n+m) is not 2 or 3,


10 if Y is vinyl, R⁴ is phenyl, Z is absent, n is 1, m is 1 and R² and R³ are ethyl, then R or R¹ is not NH₂,

if Z is absent, Y is absent or vinyl, R⁴ is phenyl, phenylalkyl, alkoxyphenyl or pyridyl, R is H and R¹ is NH₂, then R² and R³ are not A, and if Z and Y are absent, then R⁴ is not phenylalkyl

15 and their pharmaceutically tolerable salts and solvates, characterized in that

a) a compound of the formula I is liberated from one of its functional derivatives by treating with a solvolysing or hydrogenolysing agent, or

20 b) in stage 1) a compound of the formula II




25 in which


X is Cl, Br, OH or a reactive esterified OH group and

Q is NH₂ or NHA, either of which optionally is protected, and R and R¹ are optionally protected when they are or contain NH₂ or NHA,

is reacted with a compound of the formula III




in which R^2 , R^3 , Z, n and m have the meanings indicated in Claim 1,
to give a compound of formula IV



in which R, R^1 , R^2 , R^3 , Q, Z, n and m have the meanings indicated
above,

and

in stage 2) a compound of formula IV as indicated above is if necessary
deprotected to give a compound of formula IV in which Q is NH_2 or NHA
and is reacted with a compound of formula V



in which R^4 and Y have the meanings indicated in Claim 1,

or


c) a radical R, R^1 , R^2 , R^3 and/or R^4 is converted into another radical R,
 R^1 , R^2 , R^3 and/or R^4 by, for example

- converting an amino group into a guanidino group by reaction with an amidinating agent,
- reducing a nitro group, sulfonyl group or sulfoxyl group,
- etherifying an OH group or subjecting an OA group to ether cleavage,
- alkylating a primary or secondary amino group,
- partially or completely hydrolysing a CN group,
- cleaving an ester group or esterifying a carboxylic acid radical,
- reacting an aryl bromide, aryl iodide, heteroaryl bromide or heteroaryliodide to give the corresponding coupling products by means of a Suzuki coupling with boronic acids,

- or carrying out a nucleophilic or electrophilic substitution,
and/or
a base or acid of the formula I is converted into one of its salts or
solvates.

5

4. Compounds of the formula I



10

in which

R and R¹ are independently of each other H, A, OH, OA, OCH₂-Ar, Hal, NH₂, NHA, NA₂, NO₂, CN, C(O)R², CONH₂, CONHA, CONA₂, COOH, COOA or SO₂A,

15

R² and R³ are independently of each other H, A, -C(=NH)-NH₂ or solid phase,

R⁴ is Ar, cycloalkyl, phenylalkyl or Het,

Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms,

20

Z may be absent and, if present, is phenylene,

A is unbranched or branched alkyl having 1 to 6 carbon atoms,

Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,

25

Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A, Hal, OH, OA, CF₃, OCF₃, NH₂, NHA, NA₂, COOH, COOA,

30

phenyl which is unsubstituted or mono-, di- or trisubstituted by
 by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂,
 NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂ or thiophenyl
 which is unsubstituted or mono-, di- or trisubstituted by A, OH,
 5 OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂,
 NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂

Hal is F, Cl, Br or I,

n is 1, 2 or 3,

m is 0, 1, 2 or 3,

10 with the proviso

if Y is vinyl, R⁴ is phenyl, Z is absent, n is 1, m is 1 and R² and R³ are
 ethyl, then R or R¹ is not NH₂,

if Z is absent, Y is absent or vinyl, R⁴ is phenyl, phenylalkyl,
 alkoxyphenyl or pyridyl, R is H and R¹ is NH₂, then R² and R³ are not A,

15 and if Z and Y are absent, then R⁴ is not phenylalkyl

and their physiologically acceptable salts or solvates as pharmaceutical
 active compounds.

20 5. Compounds of the formula I according to Claim 4 and their
 physiologically acceptable salts or solvates as glycoprotein IbIX
 antagonists.

25 6. Compounds of the formula I according to Claim 4 and their
 physiologically acceptable salts or solvates as glycoprotein IbIX
 antagonists for the control of thrombotic disorders and sequelae deriving
 therefrom.

30 7. Pharmaceutical preparation characterized in that it contains at least one
 compound of the formula I according to Claim 4 and/or one of its
 physiologically acceptable salts or solvates.

8. Use of compounds of the formula I according to Claim 4 and/or their physiologically acceptable salts or solvates for the production of a pharmaceutical preparation for the control of thrombotic disorders and sequelae deriving therefrom or for use as anti-adhesive substances.

5

9. Use of compounds of the formula I according to Claim 4 and/or their physiologically acceptable salts or solvates for the production of a pharmaceutical preparation for the treatment of illnesses, such as for the prophylaxis and/or therapy of thrombotic disorders, as well as sequelae such as, for example, myocardial infarct, arteriosclerosis, angina pectoris, acute coronary syndromes, peripheral circulatory disorders, stroke, transient ischaemic attacks, reocclusion/restenosis after angioplasty/stent implantations or as anti-adhesive substances for implants, catheters or heart pacemakers.

10

15

20

25

30

Docket No.
Merck

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Quinazolinones

the specification of which

(check one)

- ☐ is attached hereto.
- ☒ was filed on 13.09.2000 as United States Application No. or PCT International Application Number PCT/EP00/08940 and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

99-407,958 USA 28/09/99
(Number) (Country) (Day/Month/Year Filed)

☐

(Number) (Country) (Day/Month/Year Filed)

☐

(Number) (Country) (Day/Month/Year Filed)

☐

10049155 1010203

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States of PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112. I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C.F.R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint

I. William Millen (Reg. No. 19,544)
 John L. White (Reg. No. 17,746)
 Anthony J. Zelano (Reg. No. 27,969)
 Alan E.J. Branigan (Reg. No. 20,565)
 John R. Moses (Reg. No. 24,983)
 Harry B. Shubin (Reg. No. 32,004)
 Brion P. Heaney (Reg. No. 32,542)
 Richard J. Traverso (Reg. No. 30,595)

John A. Sopp (Reg. No. 33,403)
 Richard M. Lebovitz (Reg. No. 37,067)
 John H. Thomas (Reg. No. 33,460)
 Catherine M. Joyce (Reg. No. 40,668)
 James T. Moore (Reg. No. 35,619)
 James E. Ruland (Reg. No. 37,432)
 Nancy Axelrod (Reg. No. 44,014)
 Jennifer J. Branigan (Reg. No. 40,921)

to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Send Correspondence to: MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza I
2200 Clarendon Blvd., Suite 1400
Arlington, VA 22201

Direct Telephone Calls to: (name and telephone number)

1-60

Full name of sole or first inventor	
MEDERSKI, Werner	
Sole or first inventor's	Date
<i>Werner Mederski</i>	August 21, 2002
Residence	
Katzenelnbogenweg 1, 64673 Zwingenberg, Germany	
Citizenship	DEV
German	
Post Office Address	
c/o Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany	

Full name of second inventor, if any	
DEVANT, Ralf	
Second inventor's signature	Date
DECEASED	
Residence	
Frankfurter Landstrasse 135, 64291 Darmstadt, Germany	
Citizenship	
German	
Post Office Address	
c/o Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany	

Full name of third inventor, if any
BARNICKEL, Gerhard

Third inventor's signature *Gerhard Barnickel* Date
August 21, 2002

Residence
Emilstrasse 27, 64293 Darmstadt, Germany **DEX**

Citizenship
German

Post Office Address
c/o Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany

Full name of fourth inventor, if any
BERNOTAT-DANIELOWSKI

Fourth inventor's signature *Sabine Bernotat Daniełowski* Date
August 21, 2002

Residence
Liebigstrasse 5, 61231 Bad Nauheim, Germany **DEX**

Citizenship
German

Post Office Address
Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany

Full name of fifth inventor, if any
MELZER, Guido

Fifth inventor's signature *Guido Melzer* Date
August 21, 2002

Residence
Moerikestrasse 6, 65719 Hofheim/Taunus, Germany **DEX**

Citizenship
Austria

Post Office Address
c/o Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany

Full name of sixth inventor, if any
CEZANNE, Bertram

Sixth inventor's signature *Bertram Cezanne* Date
August 21, 2002

Residence
Bahnstrasse 74, 64546 Mörfelden-Walldorf, Germany **DEX**

Citizenship
German

Post Office Address
c/o Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany

Full name of seventh inventor, if any	
DHANOA, Daljit	
seventh inventor's signature	Date
<i>Daljit Dhano</i>	August 21, 2002
Residence	
13794 Boquita Drive, Del Mar, CA 92014, USA	
Citizenship	
USA	
Post Office Address	
c/o Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany	

Full name of eighth inventor, if any	
ZHAO, Bao-Ping	
Eighth inventor's signature	Date
Residence	
5 Windsor Pond Road, West Windsor, NJ 08550, USA	
Citizenship	
CA	
Post Office Address	
c/o Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany	

Full name of ninth inventor, if any	
RINKER, James	
Ninth inventor's signature	Date
Residence	
1115 Fern Ave., Kenhorst, PA 19607, USA	
Citizenship	
USA	
Post Office Address	
c/o Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany	

Full name of tenth inventor, if any	
PLAYER, Mark	
Tenth inventor's signature	Date
Residence	
5022 Swan Dr., Phoenixville, Pa 19607, USA	
Citizenship	
USA	
Post Office Address	
c/o Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany	

Full name of seventh inventor, if any	
DHANOA, Daljit	Date
seventh inventor's signature	
Residence	
13794 Boguita Drive, Del Mar, CA 92014, USA	
Citizenship	
USA	
Post Office Address	
c/o Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany	

Full name of eighth inventor, if any	
ZHAO, Bao-Ping	Date
Eighth inventor's signature	August 21, 2002
Residence	
5 Windsor Pond Road, West Windsor, NJ 08550, USA	
Citizenship	
CA	
Post Office Address	
c/o Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany	

Full name of ninth inventor, if any	
RINKER, James	Date
Ninth inventor's signature	August 21, 2002
Residence	
1115 Fern Ave., Kenhorst, PA 19607, USA	
Citizenship	
USA	
Post Office Address	
c/o Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany	

Full name of tenth inventor, if any	
PLAYER, Mark	Date
Tenth inventor's signature	August 21, 2002
Residence	
5022 Swan Dr., Phoenixville, Pa 19607, USA	
Citizenship	
USA	
Post Office Address	
c/o Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany	

Full name of eleventh inventor, if any
SOLL, Richard

Eleventh inventor's signature **Richard Soll** Date
August 21, 2002

Residence
324 Glenn Ave., Lawrenceville, NJ 08648, USA

Citizenship
USA NJ

Post Office Address

Full name of fourth inventor, if any

Fourth inventor's signature Date

Residence

Citizenship

Post Office Address

Full name of fifth inventor, if any

Fifth inventor's signature Date

Residence

Citizenship

Post Office Address

Full name of sixth inventor, if any

Sixth inventor's signature Date

Residence

Citizenship

Post Office Address

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number
WO 01/23365 A1(51) International Patent Classification⁷: **C07D 239/91**,
239/90, A61K 31/517, A61P 7/02

(21) International Application Number: PCT/EP00/08940

(22) International Filing Date:
13 September 2000 (13.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/407,958 28 September 1999 (28.09.1999) US(71) Applicant (for all designated States except US): **MERCK
PATENT GMBH** [DE/DE]; Frankfurter Strasse 250,
64293 Darmstadt (DE).


(72) Inventors; and

(75) Inventors/Applicants (for US only): **MEDERSKI**,
Werner [DE/DE]; Am Ohlenberg 29, 64390 Erzhausen
(DE). **DEVANT, Ralf** [DE/DE]; Frankfurter Land-
strasse 135, 64291 Darmstadt (DE). **BARNICKEL**,
Gerhard [DE/DE]; Emilstrasse 27, 64298 Darmstadt
(DE). **BERNOTAT-DANIELOWSKI**, Sabine [DE/DE];
Liebigstrasse 5, 61231 Bad Nauheim (DE). **MELZER**,
Guido [DE/DE]; Mörikestrasse 6, 65719 Hofheim (DE).
DHANO, Daljit [US/US]; 2037 Skiles Blvd., West
Chester, PA 19382 (US). **ZHAO, Bao-Ping** [CN/US];3606 Hunters Glen Drive, Plainsboro, NJ 08536 (US).
RINKER, James [US/US]; 1115 Fern Avenue, Kenhurst,
PA 19607 (US). **PLAYER, Mark** [US/US]; 5022 Swan
Drive, Phoenixville, PA 19460 (US). **SOLL, Richard**
[US/US]; 324 Glenn Avenue, Lawrenceville, NJ 08648
(US).(81) Designated States (national): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ,
VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**Published:**

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: QUINAZOLINONES

(57) Abstract: Quinazolinones of formula (I) in which R, R¹, R², R³, R⁴, Y, Z, n and m have the meaning indicated in Patent Claim 1, and their salts or solvates as glycoprotein IbIX antagonists.

Attorney Docket Number: MERCK 2033A**DECLARATION FOR PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

QUINAZOLINONES

the specification of which

☐ is attached hereto

☒ was filed on 09/13/00 as United States Application Number or PCT International Application Number PCT/EP00/08940 and (if applicable) was amended on _____

I hereby authorize our attorneys to insert the serial number assigned to this application

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 USC §119			
APPLICATION NO.	COUNTRY	DAY/MONTH/YEAR FILED	PRIORITY CLAIMED
09-407,958	USA	28/09/99	YES

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

PROVISIONAL APPLICATION(S) UNDER 35 U.S.C. §119(e)	
APPLICATION NUMBER	FILING DATE

I hereby claim the benefit under 35 U.S.C. §120 of any United States application, or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

PRIOR U.S./PCT INTERNATIONAL APPLICATION(S) DESIGNATED FOR BENEFIT UNDER 37 U.S.C. §120		
APPLICATION NO.	FILING DATE	STATUS — PATENTED, PENDING, ABANDONED

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith. I. William Millen (19,544); John L. White (17,746); Anthony J. Zelano (27,969); Alan E.J. Branigan (20,565); John R. Moses (24,983); Harry B. Shubin (32,004); Brion P. Heaney (32,542); Richard J. Traverso (30,595); John A. Sopp (33,103); Richard M. Lebovitz (37,067); John H. Thomas (33,460); Catherine M. Joyce (40,668); Nancy J. Axelrod (44,014); James T. Moore (35,619); James E. Ruland (37,432); Jennifer J. Branigan (40,921) and Robert E. McCarthy (46,044)

West Chester, PA, US		UNITED STATES	
Post Office Address 2037 Skiles Blvd., West Chester, PA, US, 19382			
Full Name of additional joint inventor (given name, family name)			
Bao-Ping ZHOA			
Signature		Date	
Residence		Citizenship	
Plainsboro, NJ, US		UNITED STATES	
Post Office Address 3606 Hunters Glen Drive, Plainsboro, NJ, US, 08536			
Full Name of additional joint inventor (given name, family name)			
James RINKER			
Signature		Date	
Residence		Citizenship	
Kenhurst, PA, US		UNITED STATES	
Post Office Address 1115 Ferna Avenue, Kenhurst, PA, US, 19607			
Full Name of additional joint inventor (given name, family name)			
Mark PLAYER			
Signature		Date	
Residence		Citizenship	
Phoenixville, PA, US		UNITED STATES	
Post Office Address 5022 Swan Drive, Phoenixville, PA, US, 19460			
Full Name of additional joint inventor (given name, family name)			
Richard SOLL			
Signature		Date	
Residence		Citizenship	
Lawrenceville, NJ, US		UNITED STATES	
Post Office Address 324 Glenn Avenue, Lawrenceville, NJ, US, 08648			
Full Name of additional joint inventor (given name, family name)			
Bertram, CEZANE			
Signature		Date	
Residence		Citizenship	
Moerfelden-Walldorf, GERMANY		GERMANY	
Post Office Address Goethestrasse 47, Moerfelden-Walldorf, Germany, D-64546			

■ Additional joint inventors are named on separately numbered sheets attached hereto.

Send Correspondence to Customer Number 23599



23599

PATENT TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of sole or first inventor (given name, family name)	
Werner MEDERSKI	
Signature	Date
Residence	Citizenship
Erzhausen, GERMANY	GERMANY
Post Office Address Am Ohlenberg 29, Erzhausen, Germany, D-64390	
Full Name of additional joint inventor (given name, family name)	
Ralf DEVANT by <u>Maria Devant</u> (executor, legal representative, a citizen of DE _____) residing at Frankfurter Landstrasse 135, 64291 Darmstadt, Germany	
Signature <u>Maria Devant</u>	Date <u>19.11.2002</u>
Residence	Citizenship
	of Deceased Inventor: GERMANY
Post Office Address	
Full Name of additional joint inventor (given name, family name)	
Gerhard BARNICKEL	
Signature	Date
Residence	Citizenship
Darmstadt, GERMANY	GERMANY
Post Office Address Emilstrasse 27, Darmstadt, Germany, D-64298	
Full Name of additional joint inventor (given name, family name)	
Sabine BERNOTAT-DANIELOWSKI	
Signature	Date
Residence	Citizenship
Bad Nauheim, GERMANY	GERMANY
Post Office Address Liebigstrasse 5, Bad Nauheim, Germany, D-613231	
Full Name of additional joint inventor (given name, family name)	
Guido MELZER	
Signature	Date
Residence	Citizenship
Hofheim/Ts, GERMANY	GERMANY
Post Office Address Moerikestrasse 6, Hofheim Ts, Germany, D-65719	
Full Name of additional joint inventor (given name, family name)	
Dalijit DHANOA	
Signature	Date
Residence	Citizenship